e10vq
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2009
Commission file number 001-34435
EMDEON INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
Delaware |
|
20-5799664 |
(State or Other Jurisdiction of |
|
(I.R.S. Employer |
Incorporation or Organization) |
|
Identification No.) |
|
|
|
3055 Lebanon Pike, Suite 1000 |
|
|
Nashville, TN |
|
37214 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(615) 932-3000
(Registrants Telephone Number, Including Area Code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files). Yes
o No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Large accelerated filer o |
|
Accelerated filer o |
|
Non-accelerated filer þ
(Do not check if a smaller reporting company) |
|
Smaller reporting company o |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ
Indicate the number of shares outstanding of each of the issuers classes of common stock, as
of the latest practicable date:
|
|
|
Class |
|
Outstanding as of November 11, 2009 |
|
|
|
Class A common stock, $0.00001 par value |
|
90,238,103 |
Class B common stock, $0.00001 par value |
|
24,752,955 |
Emdeon Inc.
Table of Contents
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
1
Emdeon Inc.
Condensed Consolidated Balance Sheets
(unaudited and amounts in thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
September 30, |
|
|
|
2008 |
|
|
2009 |
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
71,478 |
|
|
$ |
194,989 |
|
Accounts receivable, net of allowance for doubtful accounts of $4,576 and $4,499
at December 31, 2008 and September 30, 2009, respectively |
|
|
144,149 |
|
|
|
152,460 |
|
Deferred income tax assets |
|
|
2,285 |
|
|
|
6,233 |
|
Prepaid expenses and other current assets |
|
|
21,137 |
|
|
|
17,272 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
239,049 |
|
|
|
370,954 |
|
Property and equipment, net |
|
|
136,038 |
|
|
|
144,324 |
|
Goodwill |
|
|
646,851 |
|
|
|
703,008 |
|
Intangible assets, net |
|
|
971,001 |
|
|
|
963,010 |
|
Other assets, net |
|
|
7,340 |
|
|
|
1,526 |
|
|
|
|
|
|
|
|
Total assets |
|
$ |
2,000,279 |
|
|
$ |
2,182,822 |
|
|
|
|
|
|
|
|
Liabilities and equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
805 |
|
|
$ |
5,623 |
|
Accrued expenses |
|
|
79,513 |
|
|
|
77,808 |
|
Deferred revenues |
|
|
12,056 |
|
|
|
12,795 |
|
Current portion of long-term debt |
|
|
17,244 |
|
|
|
5,139 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
109,618 |
|
|
|
101,365 |
|
Long-term debt, excluding current portion |
|
|
807,986 |
|
|
|
796,768 |
|
Deferred income tax liabilities |
|
|
159,811 |
|
|
|
151,869 |
|
Tax receivable agreement obligation to related parties |
|
|
|
|
|
|
141,745 |
|
Other long-term liabilities |
|
|
44,711 |
|
|
|
29,334 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
Equity: |
|
|
|
|
|
|
|
|
Preferred
stock (par value, $0.00001), 25,000,000 shares authorized and 0 shares issued and outstanding |
|
|
|
|
|
|
|
|
Class A
common stock (par value, $0.00001), 400,000,000 shares authorized and 77,413,610 and
90,238,893 shares outstanding at December 31, 2008 and September 30, 2009,
respectively |
|
|
1 |
|
|
|
1 |
|
Class B
exchangable
common stock (par value, $0.00001), 52,000,000 shares authorized and 22,586,390 and 24,752,955
shares outstanding at December 31, 2008 and September 30, 2009, respectively |
|
|
|
|
|
|
|
|
Additional paid-in capital |
|
|
670,702 |
|
|
|
732,836 |
|
Accumulated other comprehensive loss |
|
|
(23,195 |
) |
|
|
(15,511 |
) |
Retained earnings |
|
|
24,123 |
|
|
|
30,563 |
|
|
|
|
|
|
|
|
Emdeon Inc. stockholders equity |
|
|
671,631 |
|
|
|
747,889 |
|
Noncontrolling interest |
|
|
206,522 |
|
|
|
213,852 |
|
|
|
|
|
|
|
|
Total equity |
|
|
878,153 |
|
|
|
961,741 |
|
|
|
|
|
|
|
|
Total liabilities and equity |
|
$ |
2,000,279 |
|
|
$ |
2,182,822 |
|
|
|
|
|
|
|
|
See accompanying notes to the unaudited condensed consolidated financial statements.
2
Emdeon Inc.
Condensed Consolidated Statements of Operations
(unaudited and amounts in thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months |
|
For the Nine Months |
|
|
Ended September 30, |
|
Ended September 30, |
|
|
2008 |
|
2009 |
|
2008 |
|
2009 |
|
|
|
|
|
Revenue |
|
$ |
212,808 |
|
|
$ |
235,462 |
|
|
$ |
635,666 |
|
|
$ |
679,888 |
|
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations (exclusive of depreciation and amortization below) |
|
|
134,451 |
|
|
|
146,471 |
|
|
|
405,423 |
|
|
|
418,079 |
|
Development and engineering |
|
|
7,312 |
|
|
|
10,045 |
|
|
|
21,029 |
|
|
|
24,425 |
|
Sales, marketing, general and administrative |
|
|
22,220 |
|
|
|
33,823 |
|
|
|
69,309 |
|
|
|
85,146 |
|
Depreciation and amortization |
|
|
25,710 |
|
|
|
26,667 |
|
|
|
71,979 |
|
|
|
77,051 |
|
Loss on abandonment of leased properties |
|
|
|
|
|
|
482 |
|
|
|
|
|
|
|
742 |
|
|
|
|
|
|
Operating income |
|
|
23,115 |
|
|
|
17,974 |
|
|
|
67,926 |
|
|
|
74,445 |
|
Interest income |
|
|
(328 |
) |
|
|
(27 |
) |
|
|
(931 |
) |
|
|
(81 |
) |
Interest expense |
|
|
20,410 |
|
|
|
17,219 |
|
|
|
49,899 |
|
|
|
52,330 |
|
|
|
|
|
|
Income before income tax provision |
|
|
3,033 |
|
|
|
782 |
|
|
|
18,958 |
|
|
|
22,196 |
|
Income tax provision |
|
|
3,512 |
|
|
|
9,245 |
|
|
|
11,202 |
|
|
|
12,885 |
|
|
|
|
|
|
Net income (loss) |
|
|
(479 |
) |
|
|
(8,463 |
) |
|
|
7,756 |
|
|
|
9,311 |
|
Net income (loss) attributable to noncontrolling interest |
|
|
766 |
|
|
|
(1,246 |
) |
|
|
2,620 |
|
|
|
2,871 |
|
|
|
|
|
|
Net income (loss) attributable to Emdeon Inc. |
|
$ |
(1,245 |
) |
|
$ |
(7,217 |
) |
|
$ |
5,136 |
|
|
$ |
6,440 |
|
|
|
|
|
|
Net income (loss) per share Class A common stock: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.02 |
) |
|
$ |
(0.09 |
) |
|
$ |
0.07 |
|
|
$ |
0.08 |
|
|
|
|
|
|
Diluted |
|
$ |
(0.02 |
) |
|
$ |
(0.09 |
) |
|
$ |
0.07 |
|
|
$ |
0.08 |
|
|
|
|
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
77,413,610 |
|
|
|
84,522,085 |
|
|
|
73,889,095 |
|
|
|
79,809,140 |
|
|
|
|
|
|
Diluted |
|
|
77,413,610 |
|
|
|
84,522,085 |
|
|
|
73,889,095 |
|
|
|
79,856,588 |
|
|
|
|
|
|
See accompanying notes to the unaudited condensed consolidated financial statements.
3
Emdeon Inc.
Condensed Consolidated Statements of Equity
(unaudited and amounts in thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class A |
|
Class B |
|
Additional |
|
|
|
|
|
Other |
|
Non- |
|
|
|
|
Common Stock |
|
Common Stock |
|
Paid-in |
|
Retained |
|
Comprehensive |
|
Controlling |
|
Total |
|
|
Shares |
|
Amount |
|
Shares |
|
Amount |
|
Capital |
|
Earnings |
|
Income (Loss) |
|
Interest |
|
Equity |
|
|
|
Balance at January 1, 2008 |
|
|
52,000,000 |
|
|
$ |
1 |
|
|
|
48,000,000 |
|
|
$ |
|
|
|
$ |
300,550 |
|
|
$ |
14,892 |
|
|
$ |
(14,474 |
) |
|
$ |
|
|
|
$ |
300,969 |
|
Capital contribution from affiliates of General Atlantic LLC and Hellman &
Friedman LLC for the purchase of HLTH Corporations 48% interest in EBS
Master LLC on February 8, 2008 |
|
|
25,413,610 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
578,409 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
578,409 |
|
Establish non-controlling interest on February 8, 2008 |
|
|
|
|
|
|
|
|
|
|
22,586,390 |
|
|
|
|
|
|
|
(210,585 |
) |
|
|
|
|
|
|
5,435 |
|
|
|
205,150 |
|
|
|
|
|
Eliminate HLTH Corporations 48% noncontrolling interest on February 8, 2008 |
|
|
|
|
|
|
|
|
|
|
(48,000,000 |
) |
|
|
|
|
|
|
1,345 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,345 |
|
Capital contribution from stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,300 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,300 |
|
Distribution to stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(317 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(317 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,136 |
|
|
|
|
|
|
|
2,620 |
|
|
|
7,756 |
|
Change in the fair value of interest rate swap, net of taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9,594 |
) |
|
|
|
|
|
|
(9,594 |
) |
Foreign currency translation adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3 |
) |
|
|
|
|
|
|
(3 |
) |
Other comprehensive income amortization, net of taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,743 |
|
|
|
1,383 |
|
|
|
6,126 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,285 |
|
|
|
|
Balance at September 30, 2008 |
|
|
77,413,610 |
|
|
$ |
1 |
|
|
|
22,586,390 |
|
|
$ |
|
|
|
$ |
670,702 |
|
|
$ |
20,028 |
|
|
$ |
(13,893 |
) |
|
$ |
209,153 |
|
|
$ |
885,991 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at January 1, 2009 |
|
|
77,413,610 |
|
|
$ |
1 |
|
|
|
22,586,390 |
|
|
$ |
|
|
|
$ |
670,702 |
|
|
$ |
24,123 |
|
|
$ |
(23,195 |
) |
|
$ |
206,522 |
|
|
$ |
878,153 |
|
Capital contribution from stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
203 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
203 |
|
Distribution to stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(434 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(434 |
) |
Reclassification of liability awards to equity awards |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,548 |
|
|
|
|
|
|
|
|
|
|
|
6,183 |
|
|
|
26,731 |
|
Equity based compensation expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,022 |
|
|
|
|
|
|
|
|
|
|
|
832 |
|
|
|
3,854 |
|
Purchase of eRx Network L.L.C. |
|
|
|
|
|
|
|
|
|
|
1,850,000 |
|
|
|
|
|
|
|
3,530 |
|
|
|
|
|
|
|
318 |
|
|
|
19,707 |
|
|
|
23,555 |
|
Issuance of
units of EBS Master to members of management, net of taxes |
|
|
|
|
|
|
|
|
|
|
2,537,325 |
|
|
|
|
|
|
|
(11,979 |
) |
|
|
|
|
|
|
394 |
|
|
|
18,245 |
|
|
|
6,660 |
|
Issuance of Class A common stock to employees and directors, net of taxes |
|
|
349,166 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
559 |
|
|
|
|
|
|
|
(18 |
) |
|
|
(851 |
) |
|
|
(310 |
) |
Conversion of EBS Master units held by eRx to shares of Class A common stock, net of taxes |
|
|
1,850,000 |
|
|
|
|
|
|
|
(1,850,000 |
) |
|
|
|
|
|
|
21,919 |
|
|
|
|
|
|
|
(376 |
) |
|
|
(17,443 |
) |
|
|
4,100 |
|
Issuance of Class A shares in connection with initial public offering
(includes costs paid in 2008) |
|
|
10,725,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
145,211 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
145,211 |
|
Issuance of units of EBS Master to Emdeon Inc., net of taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13,799 |
|
|
|
|
|
|
|
(448 |
) |
|
|
(21,025 |
) |
|
|
(7,674 |
) |
Repurchase of Class A shares (to satisfy tax withholding obligation) |
|
|
(101,515 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,573 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,573 |
) |
Repurchase
of units of EBS Master issued to members of management, net of taxes |
|
|
|
|
|
|
|
|
|
|
(370,760 |
) |
|
|
|
|
|
|
(1,115 |
) |
|
|
|
|
|
|
(74 |
) |
|
|
(3,500 |
) |
|
|
(4,689 |
) |
Tax receivable agreement with related parties, net of taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(131,556 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(131,556 |
) |
Issuance of Class A common stock upon vesting of Restricted Stock Units |
|
|
2,632 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,440 |
|
|
|
|
|
|
|
2,871 |
|
|
|
9,311 |
|
Changes in the fair value of interest rate swap, net of taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,806 |
|
|
|
1,112 |
|
|
|
4,918 |
|
Foreign currency translation adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 |
|
|
|
6 |
|
|
|
16 |
|
Other comprehensive income amortization, net of taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,072 |
|
|
|
1,193 |
|
|
|
5,265 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19,510 |
|
|
|
|
Balance at September 30, 2009 |
|
|
90,238,893 |
|
|
$ |
1 |
|
|
|
24,752,955 |
|
|
$ |
|
|
|
$ |
732,836 |
|
|
$ |
30,563 |
|
|
$ |
(15,511 |
) |
|
$ |
213,852 |
|
|
$ |
961,741 |
|
|
|
|
See accompanying notes to the unaudited condensed consolidated financial statements.
4
Emdeon Inc.
Consolidated Statements of Cash Flows
(unaudited and amounts in thousands)
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months |
|
|
|
Ended September 30, |
|
|
|
2008 |
|
|
2009 |
|
Operating activities |
|
|
|
|
|
|
|
|
Net income |
|
$ |
7,756 |
|
|
$ |
9,311 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
71,979 |
|
|
|
77,051 |
|
Equity compensation expense |
|
|
5,813 |
|
|
|
21,499 |
|
Deferred income tax expense (benefit) |
|
|
4,925 |
|
|
|
(1,360 |
) |
Amortization of debt issuance costs |
|
|
141 |
|
|
|
143 |
|
Amortization of debt discount |
|
|
7,066 |
|
|
|
8,699 |
|
Amortization of discontinued cash flow hedge from other comprehensive income |
|
|
7,011 |
|
|
|
5,968 |
|
Change in fair value of interest rate swap |
|
|
(12,714 |
) |
|
|
|
|
Loss on abandonment of leased properties |
|
|
|
|
|
|
742 |
|
Loss on disposal of fixed assets |
|
|
72 |
|
|
|
56 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(16,968 |
) |
|
|
(3,990 |
) |
Prepaid expenses and other |
|
|
(9,760 |
) |
|
|
4,911 |
|
Accounts payable |
|
|
(3,392 |
) |
|
|
3,515 |
|
Accrued expenses and other liabilities |
|
|
(2,507 |
) |
|
|
(6,199 |
) |
Deferred revenues |
|
|
2,879 |
|
|
|
737 |
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
62,301 |
|
|
|
121,083 |
|
|
|
|
|
|
|
|
Investing activities |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(13,942 |
) |
|
|
(30,563 |
) |
Payments for acquisitions, net of cash acquired |
|
|
(19,090 |
) |
|
|
(75,871 |
) |
Purchase of EBS Master LLC |
|
|
(306,260 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(339,292 |
) |
|
|
(106,434 |
) |
|
|
|
|
|
|
|
Financing activities |
|
|
|
|
|
|
|
|
Proceeds from initial public offering |
|
|
|
|
|
|
148,261 |
|
Repurchase of Class A common stock |
|
|
|
|
|
|
(1,573 |
) |
Repurchase of Units of EBS Master LLC |
|
|
|
|
|
|
(5,372 |
) |
Debt principal payments |
|
|
(5,662 |
) |
|
|
(21,663 |
) |
Payments on revolver |
|
|
|
|
|
|
(10,201 |
) |
Payment of loan costs |
|
|
|
|
|
|
(359 |
) |
Capital contributions from stockholders |
|
|
307,451 |
|
|
|
203 |
|
Distribution to shareholders |
|
|
(317 |
) |
|
|
(434 |
) |
|
|
|
|
|
|
|
Net cash provided by financing activities |
|
|
301,472 |
|
|
|
108,862 |
|
|
|
|
|
|
|
|
Net increase in cash and cash equivalents |
|
|
24,481 |
|
|
|
123,511 |
|
Cash and cash equivalents at beginning of period |
|
|
33,687 |
|
|
|
71,478 |
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
|
$ |
58,168 |
|
|
$ |
194,989 |
|
|
|
|
|
|
|
|
See
accompanying notes to the unaudited condensed consolidated financial statements.
5
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
1. Nature of Business and Organization
Nature of Business
Emdeon Inc. (the Company) is a leading provider of revenue and payment cycle management
solutions, connecting payers, providers and patients of the U.S. healthcare system. The Companys
product and service offerings integrate and automate key business and administrative functions for
healthcare payers and healthcare providers throughout the patient encounter, including pre-care
patient eligibility and benefits verification, claims management and
adjudication, payment integrity, payment
distribution, payment posting and denial management and patient billing and payment collection.
Organization
Prior to November 2006, the group of companies that comprised Emdeon Business Services (EBS)
was owned by HLTH Corporation (HLTH). EBS Master LLC (EBS Master) was formed by HLTH to act as
a holding company for EBS. EBS Master, through its 100% owned subsidiary, Emdeon Business Services
LLC (EBS LLC), owns EBS.
In September 2006, EBS Acquisition LLC (EBS Acquisition) was formed as a Delaware limited
liability company by affiliates of General Atlantic LLC (General Atlantic). On November 16, 2006,
pursuant to the terms of an Amended and Restated Agreement and Plan of Merger, dated as of November
15, 2006, among HLTH and certain of its subsidiaries (including EBS Master) and EBS Acquisition and
two of its subsidiaries, a subsidiary of EBS Acquisition merged into a subsidiary of HLTH. As a
result of the merger, EBS Acquisition acquired a 52% interest in EBS Master, and HLTH received
approximately $1,200,000 in cash and retained a 48% interest in EBS Master. The transactions
through which EBS Acquisition acquired a 52% interest in EBS Master are referred to herein as the
2006 Transaction. The 2006 Transaction was financed with $925,000 in bank debt and an equity
investment of approximately $320,000 by EBS Acquisition. As the 2006 Transaction was deemed to be a
highly leveraged transaction, the 2006 Transaction was accounted for in accordance with Emerging
Issues Task Force (EITF) Issue No. 88-16, Basis in Leveraged Buyout Transactions, and 52% of the
net assets of EBS Master were stepped up to fair market value.
On February 8, 2008, HLTH sold its 48% noncontrolling interest in EBS Master to affiliates of
General Atlantic and Hellman & Friedman LLC (H&F) for $575,000 in cash (the 2008 Transaction).
As a result, following the 2008 Transaction, EBS Master was owned 65.77% by affiliates of General
Atlantic (including EBS Acquisition) and 34.23% by affiliates of H&F. See Note 4 for further
information related to the 2008 Transaction.
In September 2008, EBS Acquisition was converted into a Delaware corporation, and the
Companys name was changed to Emdeon Inc.
Reorganization
On August 5, 2009, the Company completed a restructuring (collectively, the reorganization
transactions) in anticipation of completing an initial public offering.
Prior to the reorganization transactions, the Company owned a 52% interest in EBS Master and
affiliates of General Atlantic and H&F owned the remaining 48% interest in EBS Master. The Company
did not engage in any business or other activities except in connection with its investment in EBS
Master and the reorganization transactions and had nominal assets other than its interest in EBS
Master. In the reorganization transactions, the Company became the sole managing member of EBS
Master and acquired additional interests in EBS Master.
Prior to the reorganization transactions, the Company was authorized to issue a single class
of common stock. In connection with the reorganization transactions, the Company amended and
restated its certificate of incorporation and is currently authorized to issue two classes of
common stock: Class A common stock and Class B common stock.
6
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
As part of the reorganization transactions:
|
|
|
The Company amended and restated its certificate of incorporation and reclassified its
outstanding common stock into an aggregate of 56,000,000 shares of its Class A common stock; |
|
|
|
|
The Company redeemed 4,000,000 shares of Class A common stock from its existing
stockholders in exchange for the rights by its existing stockholders to receive payments
under a tax receivable agreement; |
|
|
|
Another member of EBS Master, EBS Acquisition II, LLC (EBS Acquisition II), an
affiliate of General Atlantic, was merged with a newly-formed subsidiary of the Company with
the newly formed subsidiary being the surviving entity in the merger; EBS Acquisition IIs
members, all of whom are investment funds organized and controlled by General Atlantic,
received an aggregate of 13,773,913 shares of the Companys Class A common stock, and the
Company acquired, indirectly, an additional 13.52% interest in EBS Master; |
|
|
|
One of the members of EBS Master, H&F Harrington AIV I, L.P. (H&F Harrington), an
entity whose partners consist of investment funds organized and controlled by H&F, dissolved
and distributed 1.06% of its interests in EBS Master to Hellman & Friedman Investors VI,
L.P., its general partner (H&F GP), and 98.94% to H&F Harrington, Inc.; H&F Harrington,
Inc. then merged with a newly-formed subsidiary of the Company with the newly formed
subsidiary being the surviving entity in the merger; H&F Harrington, Inc.s sole
shareholder, H&F Harrington AIV II, L.P. (H&F AIV), an investment fund organized and
controlled by H&F, received an aggregate of 11,639,697 shares of the Companys Class A
common stock, and the Company acquired, indirectly, an additional 11.43% interest in EBS
Master; and |
|
|
|
Affiliates of H&F (or their successors) (the H&F Continuing LLC Members) continue to
hold an aggregate of 22,586,390 units in EBS Master (EBS Units) (or 22.18% of the
outstanding EBS Units) and were issued an aggregate of 22,586,390 shares of the Companys
Class B common stock. |
The Company accounted for the reorganization transactions using a carryover basis as the
reorganization transactions are identical ownership exchanges among entities under common control.
This is consistent with the Financial Accounting Standards Board (FASB) Accounting Standards
Codification (ASC) Business Combinations Topic. The economic interests that the affiliates of
General Atlantic and H&F held in EBS Master before the reorganization transactions did not change
as a result of the reorganization transactions.
The reorganization was accounted for similar to a transaction between entities under common
control. As EBS Acquisition II, H&F Harrington, and the H&F Continuing LLC Members did not purchase
their interests in EBS Master until the 2008 Transaction, this reorganization did not materially
impact the Companys financial statements through December 31, 2007. The financial statements for
the three month and nine month periods ended September 30, 2008 and 2009, respectively are
presented as if the H&F Continuing LLC Members represented the noncontrolling interest for the
periods subsequent to February 9, 2008.
This reorganization and the changes to the capital structure are reflected in all periods
presented.
Effective August 11, 2009, the Company priced its initial public offering of Class A common
stock (the IPO) as more fully described in Note 10 to the unaudited condensed consolidated
financial statements.
2. Basis of Presentation and Summary of Significant New Accounting Policies
Principles of Consolidation
The
accompanying unaudited condensed consolidated financial statements have been prepared in
accordance with U.S. generally accepted accounting principles for interim financial information and
with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, in the opinion of
management, reflect all normal recurring adjustments necessary for a fair presentation of results
7
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
for the unaudited interim periods presented. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with U.S. generally accepted accounting
principles have been condensed or omitted. The results of operations for the interim period are not
necessarily indicative of the results to be obtained for the full fiscal year. All material
intercompany accounts and transactions have been eliminated in the unaudited condensed consolidated
financial statements.
Reclassifications
Certain reclassifications have been made to the prior period financial statements to conform
to the current period presentation.
Recent Accounting Pronouncements
On January 1, 2009, the Company adopted the FASB ASC Business Combinations Topic. This topic
expands the definition of a business and a business combination and generally requires the
acquiring entity to recognize all of the assets and liabilities of the acquired business,
regardless of the percentage ownership acquired, at their fair values. This topic also requires
that contingent consideration and certain acquired contingencies be recorded at fair value on the
acquisition date and that acquisition costs generally be expensed as incurred. The Company recorded
approximately $391 of acquisition related expenses in the nine months ended September 30, 2009
that, absent the adoption of this topic, would have been capitalized.
These costs are included in the accompanying unaudited condensed
consolidated statement of operations within sales, marketing, general
and administrative expenses. As a result, net income for
the nine months ended September 30, 2009 was reduced by approximately $232 ($0.00 per diluted Class
A share).
On January 1, 2009, the Company adopted the provisions of the FASB ASC Fair Value Measurements
and Disclosures Topic that relate to nonfinancial assets and liabilities that are not required or
permitted to be measured at fair value on a recurring basis. Examples of such circumstances include
fair value measurements associated with the initial recognition of assets and liabilities in a
business combination and measurements of impairment following a goodwill impairment test or an
impairment of a long-lived asset other than goodwill. The adoption of this topic had no material
impact on the Companys unaudited condensed consolidated financial statements for the nine months
ended September 30, 2009.
On January 1, 2009, the Company adopted the FASB ASC Consolidation Topic as it relates to
noncontrolling interests in consolidated financial statements. The topic clarifies that a
noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that
should be reported as equity in the consolidated financial statements. Additionally, the topic
changes the way the consolidated income statement is presented by requiring consolidated net income
to be reported at amounts that include the amounts attributable to both the parent and the
noncontrolling interest. The presentation and disclosure requirements of the topic have been given
retroactive effect for all periods presented.
On January 1, 2009, the Company adopted additional disclosure provisions of the FASB ASC
Derivatives and Hedging Topic. The additional provisions amended and expanded the disclosure
requirements for derivative instruments and hedging activities with the intent to provide users of
financial statements with an enhanced understanding of how and why an entity uses derivative
instruments; how derivative instruments and related hedged items are accounted for; and how
derivative instruments and related hedged items affect an entitys financial position, financial
performance and cash flows. The topic requires qualitative disclosures about objectives and
strategies for using derivatives, quantitative disclosures about fair value amounts of gains and
losses on derivative instruments, and disclosures about credit-risk-related contingent features in
derivative agreements. The required disclosures are presented within Note 7 to the unaudited
condensed consolidated financial statements.
On April 1, 2009, the Company adopted provisions of the FASB ASC Fair Value Measurements and
Disclosures Topic (formerly outlined in FASB Staff Position 157-4, Determining Fair Value When the
Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and
Identifying Transactions That Are Not Orderly). Provisions of this topic provide additional
guidance for estimating fair value when the volume and level of activity for the asset or liability
have significantly decreased and re-emphasize that a fair value measurement is an exit price
concept as defined in the topic. Assets and liabilities measured under Level 1 inputs are excluded from the scope of these
provisions. The adoption of these provisions had no material impact on the unaudited condensed
consolidated financial statements for the nine months ended September 30, 2009.
8
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
On April 1, 2009, the Company adopted provisions of FASB ASC Fair Value Measurements and
Disclosures Topic (formerly outlined in FASB Staff Position No. 107-1 and Accounting Principles
Board Opinion 28-1, Interim Disclosures about Fair Value of Financial Instruments), to provide
disclosures on the fair value of financial instruments in interim financial statements. The
disclosures required by the topic are presented within Note 8 to the unaudited condensed
consolidated financial statements.
On April 1, 2009, the Company adopted the FASB ASC Subsequent Events Topic. The topic
establishes general standards of accounting for and disclosure of events that occur after a
companys balance sheet date but before financial statements of the company are issued or are
available to be issued. In particular, this topic sets forth: (i) the period after the balance
sheet date during which management of a reporting entity should evaluate events or transactions
that may occur for potential recognition or disclosure in the financial statements, (ii) the
circumstances under which an entity should recognize events or transactions occurring after the
balance sheet date in its financial statements and (iii) the disclosures that an entity should make
about events or transactions that occurred after the balance sheet date. Additionally, the topic
requires companies to disclose the date through which subsequent events have been evaluated as well
as the date the financial statements were issued or were available to be issued. The adoption of
the topic had no material impact on the Companys consolidated financial statements for the nine
months ended September 30, 2009. The disclosures required by the topic are presented within Note 18
to the unaudited condensed consolidated financial statements.
In August 2009, the FASB issued Accounting Standards Update 2009-05, an update to FASB ASC
Fair Value Measurements and Disclosures Topic. This update clarifies the valuation techniques to be
used by an entity to measure the fair value of a liability in circumstances in which a quoted price
in an active market for the identical liability is not available. The update further clarifies that
when estimating the fair value of a liability, a reporting entity is not required to include a
separate input or adjustment to other inputs relating to the existence of a restriction that
prevents the transfer of the liability. The guidance provided in this update is effective beginning
October 1, 2009 and is not expected to have a material impact on the unaudited condensed
consolidated financial statements of the Company.
3. Concentration of Credit Risk
The Companys revenue is generated in the United States. Changes in economic conditions,
government regulations, or demographic trends, among other matters in the United States could
adversely affect the Companys revenue and results of operations.
The Company maintains its cash and cash equivalent balances in either insured depository
accounts or a money market fund. The money market fund is subject to the limitations and
regulations of Rule 2a-7 of the Investment Company Act of 1940. As such, by law, the money market
mutual fund is limited to investments in low-risk securities such as U.S. or government agency
obligations, or repurchase agreements secured by such securities.
4. Business Combinations
Related to the 2008 Transaction, affiliates of General Atlantic and H&F were deemed to be a
collaborative group under FASB ASC 805-50-S99-2, and the 48% step up in the basis of the net assets
of EBS Master recorded at the General Atlantic and H&F acquirer level was pushed down to the
Companys financial statements in accordance with the FASB ASC Business Combinations Topic and
replaced the historical basis held by HLTH. The total purchase price of the transaction was
$578,409 and transaction costs of $3,409 were incurred. The effect of the 2008 Transaction on the
results of operations is included in the consolidated financial statements of the Company from
February 8, 2008 forward.
On September 26, 2008, the Company acquired the assets comprising the patient statement
business operated by GE Healthcare IITS USA Corp. The Company paid $16,677 in cash at closing and
incurred $391 of additional transaction-related costs. The results of operations of this business
are included in the consolidated financial statements of the Company from September 26, 2008
forward.
On June 5, 2009, the Company acquired substantially all of the assets of The Sentinel Group
from Optimal Business Services, Inc., a subsidiary of Trustmark Mutual Holding Company, for $3,067
in cash (which was funded with cash on hand). The Sentinel Group is a provider of payment integrity
solutions.
9
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
On July 2, 2009, the Company acquired all of the voting equity interests of eRx Network,
L.L.C. (eRx). eRx is a provider of electronic pharmacy healthcare solutions. The Company has
preliminarily valued the total consideration transferred for the eRx acquisition at approximately
$100,695, which consisted of approximately $74,575 in cash (funded with cash on hand), 1,850,000
EBS Units issued to certain members of eRx, valued at $13.92 per unit or approximately $25,754 in
the aggregate, and contingent consideration of approximately $366.
The total consideration transferred in connection with the eRx acquisition was allocated as
follows:
|
|
|
|
|
Cash |
|
$ |
2,889 |
|
Accounts receivable |
|
|
4,065 |
|
Other current assets |
|
|
750 |
|
Property and equipment |
|
|
7,017 |
|
Other assets |
|
|
41 |
|
Identifiable intangible assets: |
|
|
|
|
Customer contracts (20-year weighted average useful life) |
|
|
28,130 |
|
Tradename (20-year weighted average useful life) |
|
|
9,660 |
|
Non-compete agreements (5-year weighted average useful life) |
|
|
320 |
|
Goodwill (Provisional) |
|
|
53,634 |
|
Accounts payable |
|
|
(1,304 |
) |
Accrued expenses |
|
|
(4,294 |
) |
Current maturities of long-term debt |
|
|
(200 |
) |
|
|
|
|
Net assets acquired |
|
|
100,708 |
|
Noncontrolling interest |
|
|
(13 |
) |
|
|
|
|
Total consideration transferred |
|
$ |
100,695 |
|
|
|
|
|
The contingent consideration consists of a required working capital settlement whereby the
Company generally agreed to pay (receive) additional consideration to the extent that the value of
the acquired working capital exceeds (is less than) the estimated amount contemplated at the time
the merger consideration was negotiated. As of September 30, 2009, the Company estimated that it
will be required to pay additional consideration of approximately $366 upon final resolution of
this working capital settlement.
As of the acquisition date, eRx had gross contractual accounts receivable of $4,096, of which,
approximately $31 is not expected to be collected.
All
of the goodwill recorded in the eRx acquisition was assigned to the Companys pharmacy
segment. The goodwill recognized is attributable to expected synergies and the assembled workforce
of eRx. All of the goodwill recorded is expected to be deductible for income tax purposes. As of
September 30, 2009, there were no changes in the recognized amounts of goodwill resulting from the
acquisition of eRx.
The Company recognized $206 of acquisition related costs that were expensed in the nine months
ended September 30, 2009. These costs are included in the accompanying unaudited condensed
consolidated statement of operations within sales, marketing, general and administrative expenses.
10
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
The Company has not separately disclosed revenue and net income recognized in its accompanying
unaudited condensed consolidated statement of operations related to the eRx acquisition as the
operations, business and services of eRx are in the process of being integrated with the Companys
existing pharmacy segment. The following represents the pro forma consolidated revenue and net
income as if eRx had been included in the consolidated results of the Company from the beginning of
the following respective periods:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
Nine months ended |
|
|
September 30, |
|
September 30, |
|
September 30, |
|
September 30, |
|
|
2008 |
|
2009 |
|
2008 |
|
2009 |
|
|
|
|
|
Revenue |
|
$ |
219,790 |
|
|
$ |
235,462 |
|
|
$ |
655,136 |
|
|
$ |
696,585 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
369 |
|
|
$ |
(8,463 |
) |
|
$ |
9,757 |
|
|
$ |
11,256 |
|
|
|
|
|
|
5. Goodwill and Intangible Assets
Goodwill activity during the nine months ended September 30, 2009 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payer |
|
|
Provider |
|
|
Pharmacy |
|
|
Total |
|
Balance at December 31, 2008 |
|
$ |
300,909 |
|
|
$ |
315,865 |
|
|
$ |
30,077 |
|
|
$ |
646,851 |
|
Acquisitions |
|
|
2,691 |
|
|
|
|
|
|
|
53,634 |
|
|
|
56,325 |
|
Other |
|
|
50 |
|
|
|
(218 |
) |
|
|
|
|
|
|
(168 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2009 |
|
$ |
303,650 |
|
|
$ |
315,647 |
|
|
$ |
83,711 |
|
|
$ |
703,008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets subject to amortization as of September 30, 2009, consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross |
|
|
|
|
|
|
Weighted Average |
|
Carrying |
|
Accumulated |
|
|
|
|
Remaining Life |
|
Amount |
|
Amortization |
|
Net |
Customer relationships |
|
|
16.2 |
|
|
$ |
965,523 |
|
|
$ |
(109,043 |
) |
|
$ |
856,480 |
|
Trade names |
|
|
18.5 |
|
|
|
117,548 |
|
|
|
(13,156 |
) |
|
|
104,392 |
|
Non-compete agreements |
|
|
0.5 |
|
|
|
11,496 |
|
|
|
(9,358 |
) |
|
|
2,138 |
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
$ |
1,094,567 |
|
|
$ |
(131,557 |
) |
|
$ |
963,010 |
|
|
|
|
|
|
|
|
Amortization expense was $41,784 and $46,101 for the nine months ended September 30, 2008 and
2009, respectively. Aggregate future amortization expense for intangible assets is estimated to be:
|
|
|
|
|
2009 (remainder) |
|
$ |
15,694 |
|
2010 |
|
|
59,064 |
|
2011 |
|
|
58,613 |
|
2012 |
|
|
58,609 |
|
2013 |
|
|
58,507 |
|
Thereafter |
|
|
712,523 |
|
|
|
|
|
|
|
$ |
963,010 |
|
|
|
|
|
11
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
6. Long-Term Debt
Long-term debt consists of the following:
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
September 30, |
|
|
|
2008 |
|
|
2009 |
|
$50 million Revolving
line of credit facility,
expiring on November 16,
2012 and bearing interest
payable quarterly at a
variable base rate plus a
spread rate (total rate of
2.38% at December 31,
2008) |
|
$ |
10,000 |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
$755 million First Lien
Term Loan facility,
expiring on November 16,
2013, bearing interest
payable quarterly at a
variable base rate (LIBOR)
plus a spread rate (total
rate 3.46% and 2.29%) and
net of unamortized
discount of $46,833 and
$40,437 at December 31,
2008 and September 30,
2009, respectively
(combined effective
interest rate of 4.05% at
September 30, 2009) |
|
|
663,067 |
|
|
|
647,801 |
|
$170 million Second Lien
Term Loan facility,
expiring on May 16, 2014,
bearing interest at a
variable base rate (LIBOR)
plus a spread rate (total
rate 6.46% and 5.29%) and
net of unamortized
discount of $17,837 and
$15,894 at December 31,
2008 and September 30,
2009, respectively
(combined effective
interest rate of 7.88% at
September 30, 2009) |
|
|
152,163 |
|
|
|
154,106 |
|
|
|
|
|
|
|
|
|
|
Less current portion |
|
|
(17,244 |
) |
|
|
(5,139 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt |
|
$ |
807,986 |
|
|
$ |
796,768 |
|
|
|
|
|
|
|
|
On November 16, 2006, EBS LLC entered into two credit agreements with several lenders that
provided a $755,000 term loan (First Lien Term Loan), a $50,000 revolving credit agreement
(Revolver) and a $170,000 term loan (Second Lien Term Loan). In connection with these credit
agreements, EBS LLC paid fees of approximately $17,900 to the lenders of which the unamortized
portion is classified as a reduction of the carrying value of the credit agreements in each period.
Additionally, in connection with the 2008 Transaction, 48% of the carrying value of these credit
agreements was adjusted to fair value which resulted in a discount of $66,395, the unamortized
portion of which has similarly been classified as a reduction of the carrying value of the credit
agreements.
Effective July 7, 2009, the credit agreements were amended to modify the definition of a
change in control and to provide EBS LLC with the right to fund certain tax obligations, as well
as accounting, legal, and other costs of the Company (subject to an annual limit of $5,000 of these
other costs). In connection with this amendment, the Company paid fees of approximately $359 to
the lenders of which the unamortized portion is classified as a reduction of the carrying value of
the credit agreements. Additionally, the Company incurred approximately $512 of fees paid to third
parties in connection with this amendment that were expensed in the quarter ended September 30,
2009.
The Revolver expires November 2012 and provides for revolving loans not to exceed $50,000, of
which $12,000 may be used for letters of credit in support of payment obligations of the Company.
As of September 30, 2009, the Company had no borrowings outstanding, undrawn letters of credit
totaling $5,750, and $44,250 available for future borrowings under the Revolver. The Company pays a
quarterly commitment fee on the unused portion of the Revolver that fluctuates, based upon certain
leverage ratios, between 0.375% and 0.5% per annum.
The First Lien Term Loan is payable in quarterly principal installments of approximately
$1,800, plus accrued interest, beginning in March 2007 through September 2013, with a balloon
payment of the remaining principal amount outstanding due upon maturity in November 2013. These
installment payments are subject to adjustment based upon optional and mandatory prepayment
activity. Mandatory prepayments of principal related to excess cash flow, as defined, and other
circumstances are also required.
The Second Lien Term Loan is subordinate to the First Lien Term Loan and matures in May 2014.
The credit agreements require EBS LLC to maintain certain financial covenants, including a
maximum total leverage ratio and minimum interest coverage ratio. The credit agreements also impose
restrictions related to capital expenditures, investments, additional debt or liens, asset sales,
transactions with affiliates and equity interests, among other items. Additionally, the credit
agreements include restrictions on the payment of dividends or distributions (other than to fund
income tax liabilities) to or advances or loans to parties that are not party to the credit
agreements. In the case of dividends, the credit agreements generally limit payments to non-loan
parties (including the Company) with such limitations increasing based on achievement of certain
leverage ratios. Transactions with affiliates are limited to those which are approved by a majority
of the non-interested members of the EBS LLC
12
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
board of directors and whose terms are no less
favorable than those available to an unrelated person. Substantially all of the Companys net
assets are subject to the restrictions of these credit agreements. EBS LLC believes it was in
compliance with all debt covenants at September 30, 2009. This debt is secured by substantially all
of the assets of EBS LLC and is guaranteed by EBS Master.
7. Interest Rate Swap
Derivative financial instruments are used to manage the Companys interest rate exposure. The
Company does not enter into financial instruments for speculative purposes. Derivative financial
instruments are accounted for in accordance with FASB ASC Derivatives and Hedging Topic and are
measured at fair value and recorded on the balance sheet. For derivative instruments that are
designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the
derivative instrument is reported as a component of other comprehensive income and reclassified
into earnings in the same line item associated with the forecasted transaction in the same period
or periods during which the hedged transaction affects earnings (for example, in interest expense
when the hedged transactions are interest cash flows associated with floating-rate debt). The
remaining gain or loss on the derivative instrument in excess of the cumulative change in the
present value of future cash flows of the hedged item, if any, is recognized in interest expense in
current earnings during the period of change.
The following table summarizes the fair value of the Companys derivative instrument at
December 31, 2008 and September 30, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Values of Derivative Instruments |
|
|
|
Asset (Liability) Derivatives |
|
|
|
|
|
December 31, |
|
|
September 30, |
|
|
|
Balance Sheet Location |
|
2008 |
|
|
2009 |
|
Derivatives designated as hedging instruments: |
|
|
|
|
|
|
|
|
|
|
Interest rate swap |
|
Other long-term liabilities |
|
$ |
(31,244 |
) |
|
$ |
(25,648 |
) |
|
|
|
|
|
|
|
|
|
Cash Flow Hedging Relationships
Effective December 29, 2006, the Company entered into an interest rate swap agreement, which
matures in December 2011, to reduce the variability of interest payments associated with its total
long-term debt. The notional amount of the swap was $482,220 and $478,823 as of December 31, 2008
and September 30, 2009, respectively. Changes in the cash flows of the interest rate swap are
intended to offset the changes in cash flows attributable to fluctuations in the three month
variable base rates underlying the Companys long-term debt obligations. As of September 30, 2009,
$17,108 of net losses associated with the existing cash flow hedge, which have been recorded within
accumulated other comprehensive income, are expected to be reclassified to interest expense within
the next twelve months.
The 2008 Transaction represented a redesignation event. As the Companys interest rate swap
did not meet all the criteria for hedge accounting at that time, changes in the fair value
subsequent to the 2008 Transaction but prior to its redesignation as a cash flow hedge on September
30, 2008, were recorded within interest expense during the period from February 8, 2008 to
September 30, 2008. Additionally, the amortization of the amounts reflected in other comprehensive
income at the date of the 2008 Transaction related to the discontinued cash flow hedge are and
continue to be reflected within interest expense in the unaudited condensed consolidated statement
of operations. Amortization of amounts included in other comprehensive income related to the
discontinued original hedge is expected to total approximately $6,400 over the next twelve months.
13
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
The effect of the derivative instrument on the unaudited condensed consolidated statements of
operations for the three month and nine month periods ended September 30, 2008 and 2009 is
summarized in the following tables:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Location of |
|
|
Amount of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain/(Loss) |
|
|
Gain/(Loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reclassified |
|
|
Reclassified |
|
|
|
|
|
|
|
Derivatives in |
|
Amount of |
|
|
from |
|
|
from |
|
|
Location of |
|
|
|
|
Cash |
|
Gain/(Loss) |
|
|
Accumulated |
|
|
Accumulated |
|
|
Gain/(Loss) |
|
|
Gain/(Loss) Recognized |
|
Flow Hedging |
|
Recognized in OCI |
|
|
OCI into |
|
|
OCI into |
|
|
Recognized in Income |
|
|
in Income on |
|
Relationships |
|
on Derivative |
|
|
Income |
|
|
Income |
|
|
on Derivative |
|
|
Derivative |
|
|
|
(Effective |
|
|
(Effective |
|
|
(Effective |
|
|
(Ineffective Portion and Amount |
|
|
|
Portion) |
|
|
Portion) |
|
|
Portion) |
|
|
Excluded from Effectiveness Testing) |
|
For the three months ended September 30 |
|
|
|
2008 |
|
|
2009 |
|
|
|
|
|
|
2008 |
|
|
2009 |
|
|
|
|
|
2008 |
|
|
2009 |
|
Interest rate
swap |
|
|
|
|
|
$ |
1,113 |
|
|
Interest expense |
|
$ |
(6,329 |
) |
|
$ |
(7,338 |
) |
|
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the nine months ended September 30 |
|
|
|
|
|
2008 |
|
|
2009 |
|
|
|
|
|
|
2008 |
|
|
2009 |
|
|
|
|
|
|
2008 |
|
|
2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate
swap |
|
$ |
(10,980 |
) |
|
$ |
5,596 |
|
|
Interest expense |
|
$ |
(14,521 |
) |
|
$ |
(20,030 |
) |
|
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of |
|
|
|
|
|
|
|
Gain/(Loss) |
|
|
|
Location of Gain/(Loss) |
|
|
Recognized in |
|
Derivatives Not |
|
Recognized in Income on |
|
|
Income on |
|
Designated as |
|
Derivative |
|
|
Derivative |
|
Hedging Instruments |
|
Three months ended September 30 |
|
|
|
|
|
|
|
2008 |
|
|
2009 |
|
Interest rate swap |
|
Interest expense |
|
$ |
920 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended September 30 |
|
|
|
Derivative |
|
|
2008 |
|
|
2009 |
|
Interest rate swap |
|
Interest expense |
|
|
$ |
12,714 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8. Fair Value Measurements
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Companys financial assets and liabilities that are measured at fair value on a recurring
basis consist principally of the Companys derivative financial instrument. The valuation of the
Companys derivative financial instrument is determined using widely accepted valuation techniques,
including discounted cash flow analysis on the expected cash flows of each derivative. This
analysis reflects the contractual terms of the derivative, including the period to maturity, and
uses observable market-based inputs, including interest rate curves. The fair value of the interest
rate swap is determined using the market standard methodology of netting the discounted future
fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments).
The variable cash receipts (or payments) are based on an expectation of future interest rates
(forward curves) derived from observable market interest rate curves.
To comply with the provisions of FASB ASC Fair Value Measurements and Disclosures Topic, the
Company incorporates credit valuation adjustments to appropriately reflect both its own
nonperformance risk and the respective counterpartys nonperformance risk in the fair value
measurements. In adjusting the fair value of its derivative contracts for the effect of
nonperformance risk, the Company has considered the impact of netting and any applicable credit
enhancements, such as collateral postings, thresholds, mutual puts and guarantees.
14
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
The table below presents the Companys assets and liabilities measured at fair value on a
recurring basis as of September 30, 2009, aggregated by the level in the fair value hierarchy
within which those measurements fall.
Fair Value Measurements at Reporting Date Using:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Significant |
|
|
|
|
|
|
|
|
|
|
|
Significant Other |
|
|
Unobservable |
|
|
|
Balance at |
|
|
Quoted in Markets |
|
|
Observable Inputs |
|
|
Inputs |
|
Description |
|
September 30, 2009 |
|
|
Identical (Level 1) |
|
|
(Level 2) |
|
|
(Level 3) |
|
Interest Rate Swap |
|
$ |
25,648 |
|
|
|
|
|
|
$ |
25,648 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
25,648 |
|
|
|
|
|
|
$ |
25,648 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Although the Company has determined that the majority of the inputs used to value its
derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments
associated with its derivatives utilize Level 3 inputs, such as estimates of current credit spreads
to evaluate the likelihood of default by itself and by its counterparties. However, as of September
30, 2009, the Company has assessed the significance of the impact of the credit valuation
adjustments on the overall valuation of its derivative positions and has determined that the credit
valuation adjustments are not significant to the overall valuation of its derivatives. As a result,
the Company has determined that its derivative valuations in their entirety are classified in Level
2 of the fair value hierarchy.
Assets and Liabilities Measured at Fair Value upon Initial Recognition
The carrying amount and the estimated fair value of financial instruments held by the Company
as of September 30, 2009 were:
|
|
|
|
|
|
|
|
|
|
|
Carrying |
|
|
|
|
Amount |
|
Fair Value |
Cash and cash equivalents |
|
$ |
194,989 |
|
|
$ |
194,989 |
|
Accounts receivable |
|
|
152,460 |
|
|
|
152,460 |
|
Long-term debt |
|
|
801,907 |
|
|
|
825,649 |
|
The carrying amounts of cash equivalents and accounts receivable approximate fair value
because of their short-term maturities. The fair value of long-term debt is based upon market
trades by investors in partial interests of these instruments.
9. Legal Proceedings
In the normal course of business, the Company is subject to claims, lawsuits and legal
proceedings. While it is not possible to ascertain the ultimate outcome of such matters, in
managements opinion, the liabilities, if any, in excess of amounts provided or covered by
insurance, are not expected to have a material adverse effect on the Companys consolidated
financial position, results of operations or liquidity.
15
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
10. Capital Stock
Common Stock
Under the Companys amended and restated certificate of incorporation, the Company is
authorized to issue 400,000,000 shares of Class A common stock and 52,000,000 shares of Class B
common stock, each with a par value of $0.00001. The Class A and Class B common stock each provide
holders with one vote on all matters submitted to a vote of stockholders; however, the holders of
Class B common stock do not have any of the economic rights (including rights to dividends and
distributions upon liquidation) provided to the holders of the Class A common stock. Shares of
Class B common stock, together with the corresponding EBS Units, may be exchanged with the Company
for shares of Class A common stock on a one-for-one basis. All shares of the Class A and Class B
common stock generally vote together, as a single class, on all matters submitted to a vote of the
stockholders.
Preferred Stock
Under the Companys amended and restated certificate of incorporation, the Company is
authorized to issue 25,000,000 shares of preferred stock, with a par value of $0.00001 per share. As
of September 30, 2009 and December 31, 2008, there was no preferred stock outstanding.
Initial Public Offering
On August 11, 2009, the Company priced the IPO of its Class A common stock pursuant to a
Registration Statement on Form S-1 (File No. 333-153451), as amended, and Registration Statement on
Form S-1MEF (File No. 333-161270) (collectively, the Registration Statements) filed with the
Securities and Exchange Commission. In the IPO, an aggregate of 27,255,000 shares of Class A common
stock, consisting of 10,725,000 Class A shares registered on behalf of the Company and 16,530,000
Class A shares registered on behalf of selling stockholders (including 3,555,000 Class A shares
representing an over-allotment option granted by the selling stockholders to the underwriters in
the IPO) were offered and sold to the public at a price per share of $15.50. The IPO closed on
August 17, 2009, and the Company raised a total of approximately $166,238 in gross proceeds from
the IPO, or $145,211 in net proceeds after deducting underwriting commissions and other associated
costs (including approximately $3,100 of offering expenses paid in 2008).
16
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
Noncontrolling Interests
The Company has executed transactions that both increased and decreased its ownership interest
in EBS Master. These changes are summarized in the following table:
|
|
|
|
|
|
|
|
|
|
|
Nine months ended |
|
|
|
September 30, |
|
|
|
2008 |
|
|
2009 |
|
Net income attributable to Emdeon Inc. |
|
$ |
5,136 |
|
|
$ |
6,440 |
|
|
|
|
|
|
|
|
Transfers (to) from the noncontrolling interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase in Emdeon Inc. paid-in capital for issuance of 1,850,000 EBS Units
in connection with the acquisition of eRx |
|
|
|
|
|
|
3,530 |
|
|
|
|
|
|
|
|
|
|
Decrease in Emdeon Inc. paid-in capital for issuance of 2,537,325 EBS Units
to management |
|
|
|
|
|
|
(11,979 |
) |
|
|
|
|
|
|
|
|
|
Increase in Emdeon Inc. paid-in capital for the issuance of 349,166 EBS Units |
|
|
|
|
|
|
559 |
|
|
|
|
|
|
|
|
|
|
Increase in Emdeon Inc. paid-in capital related to exchange of EBS Units
held by eRx selling stockholders for shares of Emdeon Inc. Class A common
stock |
|
|
|
|
|
|
21,919 |
|
|
|
|
|
|
|
|
|
|
Increase in Emdeon Inc. paid-in capital related to the issuance of
10,354,240 EBS Units |
|
|
|
|
|
|
13,799 |
|
|
|
|
|
|
|
|
|
|
Decrease in Emdeon Inc. paid-in capital for purchase of 370,760 EBS Units
from management |
|
|
|
|
|
|
(1,115 |
) |
|
|
|
|
|
|
|
Net transfers (to) from noncontrolling interest |
|
|
|
|
|
|
26,713 |
|
|
|
|
|
|
|
|
Change from net income attributable to Emdeon Inc. and transfers (to) from noncontrolling interest |
|
$ |
5,136 |
|
|
$ |
33,153 |
|
|
|
|
|
|
|
|
11. Equity-Based Compensation Plans
Prior
to the IPO, certain employees and directors of the Company participated in one of two
equity-based compensation plansthe Amended and Restated EBS Executive Equity Incentive Plan (the
EBS Equity Plan) and the Amended and Restated EBS Incentive Plan (the EBS Phantom Plan). In
connection with the IPO, outstanding awards under the EBS Phantom Plan were converted into awards
under the 2009 Equity Incentive Plan adopted by the Companys stockholders in July 2009 (the 2009
Plan) and outstanding awards under the EBS Equity Plan were converted into EBS Units that are
governed by individual agreements with certain directors and members of executive management
(Management Awards), as well as awards under the 2009 Plan.
17
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
EBS Equity Plan
The EBS Equity Plan consisted of a class of non-voting EBS Master equity units called Grant
Units. The Grant Units represented profits interests in EBS Master. The Grant Units appreciated
with increases in value of EBS Master. All Grant Units were issued by a separate legal entity, EBS
Executive Incentive Plan LLC, which was created for this sole purpose and held no other assets.
The Grant Units generally vested ratably over a four or five year period. For all awards granted
prior to May 26, 2009, EBS Master had the right, but not the obligation, to repurchase any
employees vested units on termination of employment. If EBS Master exercised this repurchase
right, the employee would receive a cash payment based on a formula specified in the EBS Equity
Plan.
Awards under the EBS Equity Plan were historically accounted for as liabilities due to certain
repurchase features and were recorded at fair value at the end of each reporting period in
accordance with the vesting schedule. On June 26, 2009, the Company modified the terms of each of
the awards to remove the Companys ability to repurchase the Grant Units within six months of
vesting and to require that any repurchases following this six-month period be at fair value. As a
result of this modification, the Company reclassified all of the Grant Units from liability awards
to equity awards. Because the modified terms had no impact on the fair value of the Grant Units and
the awards were previously classified as liabilities, compensation expense was measured based on
the fair value of the Grant Units at the date of modification. Based on this fair value of the
Grant Units, the Company recognized equity compensation of $4,614 at that date which reduced net
income for the nine months ended September 30, 2009. No incremental compensation expense was
recognized specifically as a result of the modification.
In connection with the reorganization transactions, the Grant Units converted into (i) vested
and unvested EBS Units (together with corresponding shares of Class B common stock that have
voting, but no economic rights), (ii) options to purchase shares of Class A common stock that vest
over three years, and (iii) options to purchase shares of Class A common stock that vest over four
years. The options were granted with an exercise price equal to the IPO price. The Company has
accounted for this conversion as a modification of the original Grant Unit awards and recognized
$1,784 of incremental measured compensation, which will be attributed over the service period of
the replacement share-based payment awards.
Performance Awards
Under the EBS Equity Plan, EBS Master issued 850,000 Grant Units to the Companys executive
chairman that were earned and vested based on both continued employment (ratably over four years)
and the attainment of certain financial performance targets with respect to each of the Companys
fiscal years ending December 31, 2011 and 2012. Under the terms of the award, the number of Grant
Units that were earned and vested varied based on which, if any, of six specified financial
performance targets were satisfied for each of the Companys fiscal years ending December 31, 2011
and 2012. A maximum of 425,000 Grant Units could have been earned and vested for each of the 2011
and 2012 financial performance targets. In the event the minimum financial performance target for
either of 2011 or 2012 years were not achieved, none of the Grant Units would be earned or vest
related to that year. The Company recorded no compensation expense related to these awards as no
performance conditions had been met.
In connection with the reorganization transactions, the Grant Units with performance
conditions converted into (i) 206,578 unvested EBS Units (together with corresponding shares of
Class B common stock that have voting, but no economic rights) and (ii) 643,422 options to purchase
shares of Class A common stock with an exercise price equal to the IPO price that vest over three
years. The Company has accounted for this conversion as a modification of the original Grant Unit
award.
EBS Phantom Plan
The EBS Phantom Plan was designed to allow individual employees to participate economically in
the future growth and value creation of EBS LLC. Each participant received a specified number of
units in the EBS Phantom Plan called Phantom Units. These Phantom Units appreciated with increases
in value of EBS Master above amounts specified in the respective employees grant agreements. These
Phantom Units did not give employees an ownership interest and had no voting rights.
18
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
The Phantom Units generally vested ratably over a four or five year vesting period following
the date of grant. Upon a realization event, as defined in the EBS Phantom Plan, the holders of
these Phantom Units would receive consideration based on the product of the number of Phantom Units
earned at the time of the realization event and a formula as defined in the EBS Phantom Plan. EBS
Master had the right, but not the obligation, to repurchase any employees vested Phantom Units on
termination of employment. If EBS Master exercised this repurchase right, the employee received a
cash payment as defined in the EBS Phantom Plan. The Company accounted for these awards as
liabilities due to the existence of these repurchase features. As a result, compensation expense
was remeasured at the end of each reporting period.
In connection with the reorganization transactions, the Phantom Units converted, depending on
vesting status, into (i) shares of Class A common stock, (ii) restricted Class A common stock units
and (iii) options to purchase shares of Class A common stock with an exercise price equal to the
IPO price that vest over three years. The Company has accounted for this conversion as a
modification of the original Phantom Unit awards. In connection with this modification, the Company
calculated the final measurement of the liability at the IPO date and recognized a change in
estimate for the proportion of the Phantom Units for which the requisite service had been rendered
as of the IPO date. This change in estimate resulted in an increase to stock compensation expense
of $9,209 for the nine months ended September 30, 2009.
A summary of the status of unvested Grant Units and Phantom Units under the EBS Equity Plan
and EBS Phantom Plan, respectively, as of December 31, 2008, and changes during the nine months
ended September 30, 2009, is presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant Units |
|
|
|
|
|
|
|
|
with |
|
|
|
|
|
|
|
|
performance |
|
Phantom |
|
|
Grant Units |
|
conditions |
|
Units |
|
|
|
Unvested at December 31, 2008: |
|
|
2,834,355 |
|
|
|
|
|
|
|
1,284,133 |
|
Granted |
|
|
621,663 |
|
|
|
850,000 |
|
|
|
662,500 |
|
Canceled |
|
|
(3,342,645 |
) |
|
|
(850,000 |
) |
|
|
(1,899,833 |
) |
Vested |
|
|
(113,373 |
) |
|
|
|
|
|
|
(46,800 |
) |
|
|
|
Unvested at September 30, 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009 Plan and Management Awards
The Company reserved 17,300,000 shares of Class A common stock for issuance to employees,
directors and consultants under the 2009 Plan adopted in July 2009. The equity granted pursuant to
the 2009 Plan and Management Awards replaced outstanding awards under the EBS Equity Plan and EBS
Phantom Plan. The Management Awards included 2,537,325 vested and unvested EBS Units (206,578 of
these units are subject to performance conditions). The replacement awards issued under the 2009 Plan included
(i) 349,166 shares of Class A common stock,
(ii) 733,598 restricted Class A common stock units,
(iii) options to purchase 4,213,260 shares of Class A common stock that vest over three years
(including options to purchase 643,422 shares of Class A common stock subject to performance
conditions), and (iv) options to purchase 448,300 shares of Class A common stock that vest over
four years. As these awards were issued in connection with the conversion of the Grant Units and
Phantom Units, the fair value was derived from the allocation of the remaining compensation expense
previously associated with the Grant Units and Phantom Units to the respective share based payments
received (i.e., EBS Units, restricted Class A common stock units, shares of Class A common stock,
three year options and four year options) on a relative fair value basis.
In addition to the awards issued in connection with the conversion of the Grant Units and
Phantom Units, the Company issued options to purchase 652,000 shares of Class A common stock of the
Company that vest over four years.
19
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
EBS Units and RSUs
The EBS Units (and corresponding shares of Class B common stock) and restricted Class A common
stock units issued in connection with the conversion of the Grant Units and Phantom Units vest in
accordance with the original vesting schedule of the applicable Grant Units and Phantom Units. Upon
vesting, the EBS Units, together with the corresponding shares of Class B common stock, are
exchangeable for Class A common stock on a one-for-one basis. Upon vesting, restricted Class A
common stock units convert into Class A common stock.
As of September 30, 2009, there was $22,771 of total unrecognized compensation expense related
to unvested EBS Units and restricted Class A common stock units. This expense is expected to be
recognized over a weighted average period of 2.6 years. The total fair value of the EBS Units and
restricted Class A common stock units vested during the nine months ended September 30, 2009 was
$14,576.
Options to Purchase Shares of Class A Common Stock
Options to purchase shares of Class A common stock were granted under the 2009 Plan in
connection with the IPO both in connection with the conversion of the Grant Units and Phantom
Units, and as awards to certain employees and directors of the Company. Option awards are generally
granted with an exercise price equal to the market price of the Class A common stock on the date of
grant. The fair value of the options issued in connection with the conversion of the Grant Units
and Phantom Units was derived by the allocation of the remaining compensation expense associated
with the Grant Units and Phantom Units to the converted awards on a relative fair value basis. The
Company calculated the fair value of the new options granted under the 2009 Plan in connection with
the IPO using the Black-Scholes option pricing model.
As of September 30, 2009, unrecognized compensation expense related to options granted under
the 2009 Plan was $19,505. This expense is expected to be recognized over a weighted average period
of 3.5 years.
Performance Awards
The Company issued 206,578 unvested EBS Units and options to purchase 643,422 shares of Class
A common stock that vest over three years in connection with the conversion of Grant Units with
performance conditions held by the Companys executive chairman. The replacement awards issued are
subject to the same financial target performance condition as the Grant Units. The unvested EBS
Units and options are earned and vest based upon continued employment and the attainment of certain
financial performance objectives. The fair value of these awards was derived consistent with other
converted awards by the allocation of the remaining compensation expense of the Grant Units with
performance conditions based on relative fair value of the share based payments issued.
The fair value of the unvested EBS Units that are subject to performance conditions issued
during the nine-month period ended September 30, 2009 was $11.01 per unit. The Company has recorded
no compensation expense related to these awards as no performance conditions have been met to date.
As of September 30, 2009, there was $2,274 of total unrecognized compensation expense related to
unvested EBS Units that are subject to performance conditions.
The fair value of options granted during the nine-month period ended September 30, 2009 that
are subject to performance conditions was $5.26 per option. The Company has recorded no
compensation expense related to these awards as no performance conditions have been met to date. As
of September 30, 2009, there was $3,387 of total unrecognized compensation expense related to
options that are subject to performance conditions.
20
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
Unvested EBS Units and Restricted Class A common stock Unit Activity
A summary of the status of unvested EBS Units issued pursuant to the Management Awards and
restricted Class A common stock units issued under the 2009 Plan as of December 31, 2008, and
changes during the nine months ended September 30, 2009, is presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBS Units |
|
Restricted |
|
|
|
|
|
|
with |
|
Class A |
|
|
|
|
|
|
performance |
|
common |
|
|
EBS Units |
|
conditions |
|
stock units |
|
|
|
Unvested at December 31, 2008: |
|
|
|
|
|
|
|
|
|
|
|
|
Granted |
|
|
1,527,354 |
|
|
|
206,578 |
|
|
|
733,598 |
|
Canceled |
|
|
|
|
|
|
|
|
|
|
|
|
Vested |
|
|
(12,139 |
) |
|
|
|
|
|
|
(2,632 |
) |
|
|
|
Unvested at September 30, 2009 |
|
|
1,515,215 |
|
|
|
206,578 |
|
|
|
730,966 |
|
|
|
|
Option Activity
A summary of option activity under the 2009 Plan for the nine months ended September 30, 2009
is presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
Remaining Contractual |
|
|
|
|
Options |
|
Exercise Price |
|
Term |
|
Aggregate Intrinsic Value |
|
|
Service |
|
Performance |
|
Service |
|
Performance |
|
Service |
|
Performance |
|
Service |
|
Performance |
|
|
Options |
|
Options |
|
Options |
|
Options |
|
Options |
|
Options |
|
Options |
|
Options |
|
|
|
|
|
|
|
|
|
Outstanding at January 1, 2009 |
|
|
|
|
|
|
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
$ |
|
|
|
$ |
|
|
Replacement of cancelled awards |
|
|
4,018,138 |
|
|
|
643,422 |
|
|
|
15.50 |
|
|
|
15.50 |
|
|
|
9.9 |
|
|
|
9.9 |
|
|
|
2,813 |
|
|
|
450 |
|
Granted |
|
|
652,000 |
|
|
|
|
|
|
|
15.50 |
|
|
|
|
|
|
|
9.9 |
|
|
|
|
|
|
|
456 |
|
|
|
|
|
Forfeited |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at September 30, 2009 |
|
|
4,670,138 |
|
|
|
643,422 |
|
|
$ |
15.50 |
|
|
$ |
15.50 |
|
|
|
9.9 |
|
|
|
9.9 |
|
|
$ |
3,269 |
|
|
$ |
450 |
|
|
|
|
|
|
|
|
|
|
Vested at September 30, 2009 |
|
|
|
|
|
|
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
Exercisable at September 30, 2009 |
|
|
|
|
|
|
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
21
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
Black-Scholes Option Pricing Model Assumptions
The following table summarizes the weighted average fair values of awards valued using the
Black-Scholes option pricing model and the weighted average assumptions used to develop the fair
value estimates under each of the valuation models for the nine months ended September 30, 2009 and
2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBS Equity Plan |
|
|
|
|
|
|
|
|
|
|
|
|
Grant Units |
|
|
|
|
|
|
|
|
|
|
|
|
with |
|
|
|
|
|
|
|
|
|
|
|
|
performance |
|
2009 Equity |
|
|
EBS Equity Plan Grant Units |
|
conditions |
|
Plan Options |
|
|
Nine months |
|
Nine months |
|
Nine months |
|
Nine months |
|
|
ended |
|
ended |
|
ended |
|
ended |
|
|
September 30, |
|
September 30, |
|
September 30, |
|
September 30, |
|
|
2008 |
|
2009 |
|
2009 |
|
2009 |
Weighted average fair value |
|
$ |
7.09 |
|
|
$ |
8.51 |
|
|
$ |
6.66 |
|
|
$ |
7.55 |
|
Expected dividend yield |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected volatility |
|
|
56.00 |
% |
|
|
47.00 |
% |
|
|
47.00 |
% |
|
|
47.00 |
% |
Risk-free interest rate |
|
|
1.54 |
% |
|
|
2.50 |
% |
|
|
2.30 |
% |
|
|
2.53 |
% |
Expected term (years) |
|
|
0.47 |
|
|
|
5.6 |
|
|
|
6.4 |
|
|
|
6.25 |
|
Expected dividend yield This is an estimate of the expected dividend yield on the Class
A common stock/EBS Units. The Company is subject to limitations on the payment of dividends under
its credit facilities as further discussed in Note 6 to the unaudited condensed consolidated
financial statements. An increase in the dividend yield will decrease compensation expense.
Expected volatility This is a measure of the amount by which the price of the Class A common
stock/EBS Units has fluctuated or is expected to fluctuate. The expected volatilities are based
upon the median historical volatility of a group of peer companies, as the Class A common stock/EBS
Units has not been publicly traded for a period sufficient to estimate expected volatility. An
increase in the expected volatility will increase compensation expense.
Risk-free interest rate This is the U.S. Treasury rate for the week of the grant having a
term approximating the expected life of the award. An increase in the risk-free interest rate will
increase compensation expense.
Expected term This is the period of time over which the awards are expected to remain
outstanding. The Company estimates the expected term as the mid-point between the vesting date and
the contractual term. An increase in the expected term will increase compensation expense.
During the three months and nine months ended September 30, 2008 and 2009, the Company
recognized expense of $749, $12,554, $5,813 and $21,499, respectively, in the aggregate related to
these equity-based compensation plans.
22
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
12. Income Taxes
Income taxes for the three month and nine month periods ended September 30, 2008 and 2009
amounted to an expense of $3,512, $9,245, $11,202 and $12,885, respectively. The Companys
effective tax rate was 58.1% for the nine months ended September 30, 2009 compared with 59.1%
during the same period in 2008. The Companys effective tax rate is affected by deferred tax
expense resulting from differences between the book and income tax basis of its investment in EBS
Master. During the nine months ended September 30, 2009, the Company reduced the
amount of valuation allowance recorded against federal net operating
losses by $11,835 due to a change in
estimate of future utilization by management. Additionally, this
benefit was partially offset by an increase in the state income tax
valuation allowance related to a consolidated subsidiary in the
amount of $3,712. The Company has recorded a
valuation allowance against $227,082 of state net operating losses as of September 30, 2009.
The Company recognized a $2,532 increase in its liability for uncertain tax positions during
the nine months ended September 30, 2009 which was comprised of $1,372 related to state net
operating losses (recorded as an adjustment to the valuation allowance) and $1,160, that if
recognized, would affect the effective income tax rate.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as
follows:
|
|
|
|
|
Unrecognized benefit January 1, 2009 |
|
$ |
2,321 |
|
Increase in nine month period ended September 30, 2009 |
|
|
2,532 |
|
|
|
|
|
Unrecognized benefit September 30, 2009 |
|
$ |
4,853 |
|
|
|
|
|
The Company does not currently anticipate that the total amount of unrecognized tax positions
will significantly increase or decrease in the next twelve months. The Companys U.S. federal and
state income tax returns for tax years 2006 and beyond remain subject to examination by the
Internal Revenue Service.
The Companys policy is to record interest and penalties as a part of tax provision expense.
Due to the existence of net operating losses, no interest or penalties have been recognized in the
periods shown.
13. Tax Receivable Agreement Obligation to Related Parties
In connection with the IPO, the Company entered into tax receivable agreements which obligate
the Company to make payments to certain parties affiliated with
General Atlantic and H&F and former
Grant Unit holders generally equal to 85% of the applicable cash savings that the Company realizes
as a result of tax attributes arising from the 2006 Transaction, the
2008 Transaction and exchanges of EBS Units for cash or shares of Class A common stock. The
Company will retain the benefit of the remaining 15% of these tax savings.
All future exchanges of EBS Units for cash or shares of Class A common stock related to the
affiliates of H&F and the former Grant Unit holders who are parties to the tax
receivable agreements are expected to result in an additional tax receivable obligation for the
Company with a corresponding offset to the Companys additional paid in capital account. Subsequent
adjustments of the tax receivable obligations due to certain events (e.g. realization of net
operating losses, tax rate changes or the timing of cash settlement obligations) are expected to
result in a corresponding adjustment of the Companys net income.
23
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
14. Net Income (Loss) Per Share
The following table sets forth the computation of basic and diluted net income (loss) per
share of Class A common stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2008 |
|
|
2009 |
|
|
2008 |
|
|
2009 |
|
Basic net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to Emdeon Inc. |
|
$ |
(1,245 |
) |
|
$ |
(7,217 |
) |
|
$ |
5,136 |
|
|
$ |
6,440 |
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding |
|
|
77,413,610 |
|
|
|
84,522,085 |
|
|
|
73,889,095 |
|
|
|
79,809,140 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net income (loss) per share |
|
$ |
(0.02 |
) |
|
$ |
(0.09 |
) |
|
$ |
0.07 |
|
|
$ |
0.08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to Emdeon Inc. |
|
$ |
(1,245 |
) |
|
|
|
|
|
$ |
5,136 |
|
|
|
|
|
Net loss excluding EBS Master |
|
|
|
|
|
$ |
(3,346 |
) |
|
|
|
|
|
$ |
(3,804 |
) |
Weighted average effect of dilutive securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Add: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Emdeon Inc. allocation of EBS Master net income (loss) |
|
|
|
|
|
|
(4,011 |
) |
|
|
|
|
|
|
10,169 |
|
Impact of exchange of Class B shares on income
attributable to Emdeon Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
(1,245 |
) |
|
$ |
(7,357 |
) |
|
$ |
5,136 |
|
|
$ |
6,365 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares used in basic computation |
|
|
77,413,610 |
|
|
|
84,522,085 |
|
|
|
73,889,095 |
|
|
|
79,809,140 |
|
Weighted average effect of dilutive securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Add: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted
Class A common stock units |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
47,448 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
77,413,610 |
|
|
|
84,522,085 |
|
|
|
73,889,095 |
|
|
|
79,856,588 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income (loss) per share |
|
$ |
(0.02 |
) |
|
$ |
(0.09 |
) |
|
$ |
0.07 |
|
|
$ |
0.08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Due to their antidilutive effect, the following securities have been excluded from
diluted net income (loss) per share for the respective periods:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
Three Months |
|
Nine Months |
|
Nine Months |
|
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
|
September 30, |
|
September 30, |
|
September |
|
September |
|
|
2008 |
|
2009 |
|
30, 2008 |
|
30, 2009 |
Class B common stock |
|
|
22,586,390 |
|
|
|
23,658,441 |
|
|
|
26,110,905 |
|
|
|
22,947,667 |
|
Options to purchase Class A common stock |
|
|
|
|
|
|
2,588,881 |
|
|
|
|
|
|
|
872,443 |
|
Restricted Class A common stock units |
|
|
|
|
|
|
142,344 |
|
|
|
|
|
|
|
|
|
24
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
15. Loss on Abandonment of Leased Properties
In September 2009, the Company paid a fee of $241 for early termination of a lease in Jessup,
Maryland. The Company expects to cease use of the property by the end of 2009. During December
2008, the Company ceased use of property subject to operating leases in Nashville, Tennessee and
Scottsdale, Arizona.
The following table summarizes the activity related to these contract termination costs:
|
|
|
|
|
Balance at December 31, 2008 |
|
$ |
3,203 |
|
Costs incurred |
|
|
742 |
|
Costs paid or otherwise settled |
|
|
(1,842 |
) |
|
|
|
|
Balance at September 30, 2009 |
|
$ |
2,103 |
|
|
|
|
|
The estimate of the original loss, as well as all subsequent amortization associated with the
abandonment of these leases, is classified within loss on abandonment of leased properties in the
accompanying unaudited condensed consolidated statement of operations.
16. Segment Reporting
Management views the Companys operating results in three reportable segments: (i) payer
services, (ii) provider services and (iii) pharmacy services. Listed below are the results of
operations for each of the reportable segments. This information is reflected in the manner
utilized by management to make operating decisions, assess performance and allocate resources. The
accounting policies of the reportable segments are the same as those described in the summary of
significant accounting policies in the notes to the Companys 2008 audited consolidated financial
statements included in the Registration Statements.
Payer Services Segment
The payer services segment provides claims management and payment distribution products and
services to healthcare payers, both directly and through the Companys channel partners, that
simplify the administration of healthcare related to insurance eligibility and benefit
verification, claims filing, payment integrity and claims and payment distribution.
Provider Services Segment
The provider services segment provides revenue cycle management solutions, patient billing and
payment services and dental services to healthcare providers, both directly and through the
Companys channel partners, that simplify the providers revenue cycle, reduce related costs and
improve cash flow.
Pharmacy Services Segment
The
pharmacy services segment provides solutions and services to
pharmacies and pharmacy benefit management companies and government
agencies related to prescription benefit claim filing,
adjudication and management, as well as electronic prescriptions.
Other
Inter-segment revenue and expenses primarily represent claims management and patient statement
services provided between segments.
Corporate and eliminations includes personnel and other costs associated with the Companys
management, administrative and other corporate services functions and eliminations to remove
inter-segment revenues and expenses.
The revenue and total segment contribution for the reportable segments are as follows:
25
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
For the Three Months Ended September 30, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate & |
|
|
|
|
|
|
Payer |
|
|
Provider |
|
|
Pharmacy |
|
|
Eliminations |
|
|
Consolidated |
|
Revenue from external customers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Claims management |
|
$ |
44,066 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
44,066 |
|
Payment services |
|
|
48,699 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
48,699 |
|
Patient statements |
|
|
|
|
|
|
66,279 |
|
|
|
|
|
|
|
|
|
|
|
66,279 |
|
Revenue cycle management |
|
|
|
|
|
|
36,256 |
|
|
|
|
|
|
|
|
|
|
|
36,256 |
|
Dental |
|
|
|
|
|
|
7,939 |
|
|
|
|
|
|
|
|
|
|
|
7,939 |
|
Pharmacy services |
|
|
|
|
|
|
|
|
|
|
9,569 |
|
|
|
|
|
|
|
9,569 |
|
Inter-segment revenues |
|
|
77 |
|
|
|
512 |
|
|
|
|
|
|
|
(589 |
) |
|
|
|
|
|
|
|
Net revenue |
|
|
92,842 |
|
|
|
110,986 |
|
|
|
9,569 |
|
|
|
(589 |
) |
|
|
212,808 |
|
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations |
|
|
60,528 |
|
|
|
72,546 |
|
|
|
1,816 |
|
|
|
(439 |
) |
|
|
134,451 |
|
Development and engineering |
|
|
2,655 |
|
|
|
3,608 |
|
|
|
1,049 |
|
|
|
|
|
|
|
7,312 |
|
Sales, marketing, general and administrative |
|
|
6,004 |
|
|
|
7,136 |
|
|
|
1,002 |
|
|
|
8,078 |
|
|
|
22,220 |
|
|
|
|
Segment contribution |
|
$ |
23,655 |
|
|
$ |
27,696 |
|
|
$ |
5,702 |
|
|
$ |
(8,228 |
) |
|
|
48,825 |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,710 |
|
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(328 |
) |
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,410 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income tax provision |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
3,033 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended September 30, 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate & |
|
|
|
|
|
|
Payer |
|
|
Provider |
|
|
Pharmacy |
|
|
Eliminations |
|
|
Consolidated |
|
Revenue to external customers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Claims management |
|
$ |
46,072 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
46,072 |
|
Payment services |
|
|
53,345 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
53,345 |
|
Patient statements |
|
|
|
|
|
|
69,840 |
|
|
|
|
|
|
|
|
|
|
|
69,840 |
|
Revenue cycle management |
|
|
|
|
|
|
39,041 |
|
|
|
|
|
|
|
|
|
|
|
39,041 |
|
Dental |
|
|
|
|
|
|
7,978 |
|
|
|
|
|
|
|
|
|
|
|
7,978 |
|
Pharmacy services |
|
|
|
|
|
|
|
|
|
|
19,186 |
|
|
|
|
|
|
|
19,186 |
|
Inter-segment revenue |
|
|
297 |
|
|
|
416 |
|
|
|
|
|
|
|
(713 |
) |
|
|
|
|
|
|
|
Total revenue |
|
|
99,714 |
|
|
|
117,275 |
|
|
|
19,186 |
|
|
|
(713 |
) |
|
|
235,462 |
|
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations |
|
|
65,805 |
|
|
|
75,070 |
|
|
|
6,158 |
|
|
|
(562 |
) |
|
|
146,471 |
|
Development and engineering |
|
|
3,847 |
|
|
|
4,297 |
|
|
|
1,901 |
|
|
|
|
|
|
|
10,045 |
|
Sales, marketing, general and administrative |
|
|
8,037 |
|
|
|
9,038 |
|
|
|
3,413 |
|
|
|
13,335 |
|
|
|
33,823 |
|
Loss on abandonment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
482 |
|
|
|
482 |
|
|
|
|
Segment contribution |
|
$ |
22,025 |
|
|
$ |
28,870 |
|
|
$ |
7,714 |
|
|
$ |
(13,968 |
) |
|
|
44,641 |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,667 |
|
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(27 |
) |
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,219 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income tax provision |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
782 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
For the Nine Months Ended September 30, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate & |
|
|
|
|
|
|
Payer |
|
|
Provider |
|
|
Pharmacy |
|
|
Eliminations |
|
|
Consolidated |
|
Revenue from external customers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Claims management |
|
$ |
134,621 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
134,621 |
|
Payment services |
|
|
142,522 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
142,522 |
|
Patient statements |
|
|
|
|
|
|
198,500 |
|
|
|
|
|
|
|
|
|
|
|
198,500 |
|
Revenue cycle management |
|
|
|
|
|
|
106,894 |
|
|
|
|
|
|
|
|
|
|
|
106,894 |
|
Dental |
|
|
|
|
|
|
23,938 |
|
|
|
|
|
|
|
|
|
|
|
23,938 |
|
Pharmacy services |
|
|
|
|
|
|
|
|
|
|
29,191 |
|
|
|
|
|
|
|
29,191 |
|
Inter-segment revenues |
|
|
298 |
|
|
|
1,647 |
|
|
|
|
|
|
|
(1,945 |
) |
|
|
|
|
|
|
|
Net revenue |
|
|
277,441 |
|
|
|
330,979 |
|
|
|
29,191 |
|
|
|
(1,945 |
) |
|
|
635,666 |
|
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations |
|
|
182,838 |
|
|
|
218,311 |
|
|
|
5,687 |
|
|
|
(1,413 |
) |
|
|
405,423 |
|
Development and engineering |
|
|
7,453 |
|
|
|
10,472 |
|
|
|
3,104 |
|
|
|
|
|
|
|
21,029 |
|
Sales, marketing, general and administrative |
|
|
18,727 |
|
|
|
22,888 |
|
|
|
2,896 |
|
|
|
24,798 |
|
|
|
69,309 |
|
|
|
|
Segment contribution |
|
$ |
68,423 |
|
|
$ |
79,308 |
|
|
$ |
17,504 |
|
|
$ |
(25,330 |
) |
|
|
139,905 |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
71,979 |
|
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(931 |
) |
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
49,899 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income tax provision |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
18,958 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended September 30, 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate & |
|
|
|
|
|
|
Payer |
|
|
Provider |
|
|
Pharmacy |
|
|
Eliminations |
|
|
Consolidated |
|
Revenue to external customers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Claims management |
|
$ |
137,440 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
137,440 |
|
Payment services |
|
|
156,433 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
156,433 |
|
Patient statements |
|
|
|
|
|
|
207,304 |
|
|
|
|
|
|
|
|
|
|
|
207,304 |
|
Revenue cycle management |
|
|
|
|
|
|
114,825 |
|
|
|
|
|
|
|
|
|
|
|
114,825 |
|
Dental |
|
|
|
|
|
|
23,690 |
|
|
|
|
|
|
|
|
|
|
|
23,690 |
|
Pharmacy services |
|
|
|
|
|
|
|
|
|
|
40,196 |
|
|
|
|
|
|
|
40,196 |
|
Inter-segment revenue |
|
|
434 |
|
|
|
1,388 |
|
|
|
|
|
|
|
(1,822 |
) |
|
|
|
|
|
|
|
Total revenue |
|
|
294,307 |
|
|
|
347,207 |
|
|
|
40,196 |
|
|
|
(1,822 |
) |
|
|
679,888 |
|
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations |
|
|
188,094 |
|
|
|
221,464 |
|
|
|
9,947 |
|
|
|
(1,426 |
) |
|
|
418,079 |
|
Development and engineering |
|
|
9,172 |
|
|
|
11,283 |
|
|
|
3,970 |
|
|
|
|
|
|
|
24,425 |
|
Sales, marketing, general and administrative |
|
|
20,461 |
|
|
|
24,335 |
|
|
|
5,439 |
|
|
|
34,911 |
|
|
|
85,146 |
|
Loss on abandonment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
742 |
|
|
|
742 |
|
|
|
|
Segment contribution |
|
$ |
76,580 |
|
|
$ |
90,125 |
|
|
$ |
20,840 |
|
|
$ |
(36,049 |
) |
|
|
151,496 |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
77,051 |
|
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(81 |
) |
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52,330 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income tax provision |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
22,196 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27
Emdeon Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited and amounts in thousands, except share and per share amounts)
17. Accumulated Other Comprehensive (Loss) Income
The following is a summary of accumulated other comprehensive income (loss) balances, net of
taxes and noncontrolling interest, as of and for the nine-month period ended September 30, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign |
|
Net Losses |
|
|
|
|
|
Accumulated |
|
|
Currency |
|
on Cash Flow |
|
Discontinued |
|
Other |
|
|
Translation |
|
Hedging |
|
Cash Flow |
|
Comprehensive |
|
|
Adjustment |
|
Derivatives |
|
Hedge |
|
Income |
|
|
|
Balance at December 31, 2008 |
|
$ |
(49 |
) |
|
$ |
(11,095 |
) |
|
$ |
(12,051 |
) |
|
$ |
(23,195 |
) |
Change associated with foreign currency translation |
|
|
10 |
|
|
|
|
|
|
|
|
|
|
|
10 |
|
Change associated with current period hedging |
|
|
|
|
|
|
(10,348 |
) |
|
|
|
|
|
|
(10,348 |
) |
Reclassification into earnings |
|
|
|
|
|
|
14,062 |
|
|
|
3,960 |
|
|
|
18,022 |
|
|
|
|
Balance at September 30, 2009 |
|
$ |
(39 |
) |
|
$ |
(7,381 |
) |
|
$ |
(8,091 |
) |
|
$ |
(15,511 |
) |
|
|
|
18. Subsequent Events
On October 1, 2009, the Company sold substantially all of the long-lived assets associated
with its office supplies & print services business for cash of approximately $1,300. The Company
expects to recognize a gain on sale of this business of approximately
$500 in its fiscal fourth
quarter of 2009.
In
October 2009, the Company acquired certain additional rights to specified uses of its
data from HLTH in order to broaden the Companys ability to pursue business intelligence and data
analytics solutions for payers and providers. The Company previously licensed exclusive rights to
this data to HLTH pursuant to an Amended and Restated Data License Agreement in connection with the
2008 Transaction. The Company expects to record an amortizable intangible asset with an estimated
life of approximately eight years and an obligation of approximately
$43,259 based on the present
value of the scheduled annual payments through 2018. Additionally, the Company has an option,
exercisable within seven months of execution of the agreement, to acquire additional data rights.
If this option is exercised, an additional amortizable intangible asset and related obligation of
approximately $6,300 based on the present value of the payments would be recorded at that time.
The
Company has evaluated subsequent events through November 12, 2009, the date the
financial statements were issued.
28
|
|
|
ITEM 2. |
|
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
The
following discussion and analysis should be read in conjunction with
the unaudited condensed
consolidated financial statements and the accompanying notes included in Part I, Item 1 of this
Quarterly Report on Form 10-Q (Quarterly Report), with the risk factors contained in the section
titled Risk Factors in our Registration Statement on Form S-1, as amended (File No. 333-153451)
(the Registration Statement) on file with the Securities and Exchange Commission (SEC) for our
initial public offering (IPO) of our Class A common stock completed in August 2009.
Unless stated otherwise or the context otherwise requires, references in this Quarterly Report
to we, us, our, Emdeon and the Company refer to Emdeon Inc. and its subsidiaries.
Forward-Looking Statements
This Quarterly Report contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. You should not place undue reliance on those
statements because they are subject to numerous uncertainties and factors relating to our
operations and business environment, all of which are difficult to predict and many of which are
beyond our control. Forward-looking statements include information concerning our possible or
assumed future results of operations, including descriptions of our business strategy. These
statements often include words such as may, will, should, believe, expect, anticipate,
intend, plan, estimate or similar expressions. These statements are based upon assumptions
that we have made in light of our experience in the industry, as well as our perceptions of
historical trends, current conditions, expected future developments and other factors we believe
are appropriate under the circumstances. As you read this Quarterly Report, you should understand
that these statements are not guarantees of performance or results. They involve known and unknown
risks, uncertainties and assumptions. Although we believe that these forward-looking statements are
based upon reasonable assumptions, you should be aware that many factors could affect our actual
financial results or results of operations and could cause actual results to differ materially from
those in the forward-looking statements. For further information about these and other factors that
could affect our future results, please see the risk factors contained in the section titled Risk
Factors in our Registration Statement.
Our forward looking statements made herein speak only as of the date on which made. We
expressly disclaim any intent, obligation or undertaking to update or revise any forward-looking
statements made herein to reflect any change in our expectations with regard thereto or any change
in events, conditions or circumstances on which any such statements are based. All subsequent
written and oral forward-looking statements attributable to us or persons acting on our behalf are
expressly qualified in their entirety by the cautionary statements contained in this Quarterly
Report.
Overview
We are a leading provider of revenue and payment cycle management solutions, connecting
payers, providers and patients in the U.S. healthcare system. Our product and service offerings
integrate and automate key business and administrative functions of our payer and provider
customers throughout the patient encounter, including pre-care patient eligibility and benefits
verification, claims management and adjudication, payment integrity, payment distribution, payment
posting and denial management, patient billing and payment. Our customers are able to improve
efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and
payment cycle process by using our comprehensive suite of products and services.
We deliver our solutions and operate our business in three business segments: (i) payer
services, which provides solutions to commercial insurance companies, third party administrators and
governmental payers; (ii) provider services, which provides solutions to hospitals, physicians,
dentists and other healthcare providers, such as labs and home healthcare providers; and (iii)
pharmacy services, which provides solutions to pharmacies, pharmacy benefit management companies and
other payers. Through our payer services segment, we provide payment cycle solutions, both directly
and through our channel partners, that simplify the administration of healthcare related to
insurance eligibility and benefit verification, claims filing and claims, payment integrity and
payment distribution. Through our provider services segment, we provide revenue cycle management
solutions and patient billing and payment services, both directly and through our channel partners,
that simplify providers revenue cycle, reduce related costs and improve cash flow. Through our
pharmacy services segment, we provide solutions to pharmacies and pharmacy benefit management
companies and government agencies related to prescription benefit claim filing, adjudication and
management, as well as electronic prescriptions.
29
There are a number of company-specific initiatives and industry trends that may affect our
transaction volumes, revenues, cost of operations and margins. As part of our strategy, we
encourage our customers to migrate from paper-based claim, patient statement, payment and other
transaction processing to electronic, automated processing in order to improve efficiency. Our
business is aligned with our customers to support this transition, and as they migrate from
paper-based transaction processing to electronic processing, even though our revenues generally
will decline, our margins and profitability will typically increase. For example, because the cost
of postage is included in our revenues for patient statement and payment distribution services
(which is then also deducted as a cost of operations), when our customers transition to electronic
processing, our revenues and costs of operations decrease as we will no longer incur or be required
to charge for postage. In addition, if our payer customers migrate to exclusive eligibility and
benefits verification and/or claims management services agreements with us, which we refer to as
Managed Gateway Agreements (MGAs), our electronic transaction volume usually increases while the
rebates we pay and the per transaction rate we charge under these agreements is typically reduced.
Part of our strategy also includes acquisitions and the development and introduction of new
products and services, such as information based business intelligence and data analytics solutions
and electronic payment solutions for payers and providers. As we expand our business, these new and
updated products and services will require us to continue to invest capital and operating resources
in the development, production and marketing of these solutions in order to successfully develop
and achieve market acceptance of such products and services. Excluding the equity-based compensation expense incurred during the
third quarter of 2009 in connection with the IPO, we currently estimate our annual
development and engineering expenses for 2009 and 2010 to be in the range of approximately 3.7% to
4.1% of revenue. We expect to fund such expenditures with cash flows generated from operations. We
also may acquire, or enter into agreements with third parties to assist us in providing,
new products and services. For example, we offer, or plan to offer, our electronic payment
solutions through banks or vendors who contract with banks and other financial service firms. The
costs of these initiatives or the failure to achieve broad penetration in target markets with
respect to new or updated products and services may negatively affect our results of operations and margins.
We also expect to continue to be affected by pricing pressure in our industry, which has led
(and is expected to continue to lead) to reduced prices for the same services. We have sought in
the past and will continue to seek to mitigate pricing pressure by (i) providing additional
value-added products and services, (ii) increasing the volume of services we provide and (iii)
managing our costs. In addition, significant changes in regulatory schemes, such as the new updated
Health Insurance Portability and Accountability Act of 1996 (HIPAA) standard electronic
transaction code set requirements for ICD-10, American Recovery and Reinvestment Act of 2009
(ARRA) and other federal healthcare policy initiatives, and demographic trends affecting the
healthcare industry, such as population growth and aging, could affect the frequency and nature of
our customers healthcare transactional activity. The impact of such changes could impact our
revenues, cost of operations and infrastructure expenses and thereby affect our results of
operations and the way we operate our business. For example, an increase in the U.S. population, if
such increase is accompanied by an increase in the U.S. population that has health benefits, or the
aging of the U.S. population, which requires an overall increased need for healthcare services, may
result in an increase in our transaction volumes which, in turn, may increase our revenues and
costs of operations.
Organizational Structure
The Company is a Delaware corporation. A brief history of our organizational structure is as
follows:
|
|
|
Prior to November 2006, the group of companies that comprised Emdeon Business Services
(EBS) was owned by HLTH Corporation (HLTH). EBS Master LLC (EBS Master) was formed by
HLTH to act as a holding company for EBS. EBS Master, through its 100% owned subsidiary,
Emdeon Business Services LLC (EBS LLC), owns EBS. |
|
|
|
In September 2006, we were formed by General Atlantic LLC (General Atlantic) as a
Delaware limited liability company for the purpose of making an investment in EBS Master.
In November 2006, we acquired a 52% interest in EBS Master from HLTH (the 2006
Transaction). HLTH retained a 48% interest in EBS Master upon closing of the 2006
Transaction. |
|
|
|
In February 2008, HLTH sold its remaining 48% interest in EBS Master (the 2008
Transaction) to affiliates of General Atlantic and Hellman & Friedman LLC (H&F). As a
result, following the 2008 Transaction, EBS Master was owned 65.77% by affiliates of
General Atlantic (including us) and 34.23% by affiliates of H&F. General Atlantic and H&F
are sometimes referred to herein as the Principal Equityholders. |
30
|
|
|
In anticipation of completing our IPO, we were converted into a Delaware corporation and
changed our name to Emdeon Inc. in September 2008 and completed a corporate restructuring
on August 5, 2009 (collectively, the reorganization transactions). |
Recent Developments
On July 2, 2009, we acquired eRx Network, L.L.C. (eRx), a provider of electronic pharmacy
healthcare solutions. We believe the acquisition of eRx will accelerate our development of
solutions for our pharmacy customers, including integrated tools for managing efficiency and
profitability through innovative claims management, and will provide the combined organization with
an increased presence in ePrescribing. The consideration transferred in connection with the eRx
acquisition consisted of cash of approximately $74.6 million and 1,850,000 of EBS Master units (the
EBS Units).
On August 11, 2009, the Company priced the IPO of its Class A common stock pursuant to the
Registration Statement and a Registration Statement on Form S-1MEF (File No. 333-161270)
(collectively, with the Registration Statement, the Registration Statements). In the IPO, an
aggregate of 27,255,000 shares of Class A common stock, consisting of 10,725,000 Class A shares
registered on behalf of the Company and 16,530,000 Class A shares registered on behalf of selling
stockholders (including 3,555,000 Class A shares representing an over-allotment option granted by
the selling stockholders to the underwriters in the IPO), were offered and sold to the public at a
price per share of $15.50. The IPO closed on August 17, 2009, and the Company raised a total of
approximately $166.2 million in gross proceeds from the IPO, or $145.2 million in net proceeds
after deducting underwriting commissions and other associated costs (including approximately $3.1
million of offering expenses paid in 2008).
On October 1, 2009, the Company sold substantially all of the long-lived assets associated
with its office supplies and print services business for cash of approximately $1.3 million. The
Company expects to recognize a gain on sale of this business of
approximately $0.5 million in the fourth quarter of 2009.
In
October 2009, the Company acquired certain additional rights to specified uses of its
data from HLTH in order to broaden the Companys ability to pursue business intelligence and data
analytics solutions for payers and providers. The Company previously licensed exclusive rights to
this data to HLTH pursuant to an Amended and Restated Data License Agreement in connection with the
2008 Transaction. The Company expects to record an amortizable intangible asset with an estimated
life of approximately eight years and an obligation of approximately
$43.3 million based on the present
value of the scheduled annual payments through 2018. Additionally, the Company has an option,
exercisable within seven months of execution of the agreement, to acquire additional data rights.
If this option is exercised, an additional amortizable intangible asset and related obligation of
approximately $6.3 million based on the present value of the payments would be recorded at that time.
Our Revenues and Expenses
We generate revenues by providing products and services that automate and simplify business
and administrative functions for payers and providers, generally on either a per transaction, per
document, per communications basis or, in some cases, on a monthly flat-fee basis. We generally
charge a one-time implementation fee to payers and providers at the inception of a contract in
conjunction with related setup and connection to our network and other systems. In addition, we
receive software license fees and software and hardware maintenance fees, primarily from payers who
license our systems for converting paper claims into electronic ones.
Cost of operations consists primarily of costs related to products and services we provide to
customers and costs associated with the operation and maintenance of our networks. These costs
include (i) postage and materials costs related to our patient statement and billing and payment
distribution services, (ii) rebates paid to our channel partners, including healthcare information
system vendors and electronic medical record vendors and (iii) data communications costs, all of
which generally vary with our revenues. Cost of operations also includes (i) personnel costs
associated with production, network operations, customer support and other personnel, (ii)
facilities expenses and (iii) equipment maintenance, which vary less directly with our revenue due
to the fixed or semi-fixed nature of these expenses.
31
The largest component of our cost of operations is currently postage (which is also a
component of our revenue). Our postage costs increase as our patient statement and payment
distribution volumes increase and also when the U.S. Postal Service increases postal rates. U.S.
postage rate increases, while generally billed as pass-through costs to our customers, affect our
cost of operations as a percentage of revenue. In recent years, we have offset the impact of
postage rate increases through cost reductions from efficiency measures, including data
communication expense reductions and production efficiencies. Though we plan to continue our
efficiency measures, we may not be able to offset the impact of postage rate increases in the
future and, as a result, cost of operations as a percentage of revenue may rise if postage rate
increases continue. Although the U.S. Postal Service has increased postal rates annually from 2006
to 2009, such annual increases may not occur as regularly in the future. For example, although not
yet certain, preliminary indications from the U.S. Postmaster General are that postal rate
increases will not occur during 2010.
Rebates are paid to channel partners for electronic and other volumes delivered through our
network to certain payers and can be impacted by the number of MGAs we execute with payers, the
success of our direct sales efforts for provider revenue cycle management products and services and
the extent to which direct connections to payers are developed by channel partners.
Our data communication expense consists of telecommunication and transaction processing
charges. Over the last several years, we have been able to reduce our data communication expense
due to efficiency measures and contract pricing changes.
Our
material costs relate primarily to our patient statement and payment distribution volumes,
and consist primarily of paper and printing costs.
Development and engineering expense consists primarily of personnel costs related to the
development, management and maintenance of our current and future products and services. We may
invest more in this area in the future as we develop new products and enhance existing products.
Sales, marketing, general and administrative expense (excluding corporate expense described in
the next paragraph) consists primarily of personnel costs associated with our sales, account
management and marketing functions and management and administrative services related to the
operations of our business segments.
Our corporate expense relates to personnel costs associated with management, administrative,
finance, human resources, legal, marketing, public relations and other corporate service functions,
as well as professional services, costs incurred in connection with acquisitions, certain
facilities costs, advertising and promotion, insurance and other expenses related to our overall
business operations. Since our IPO, we have incurred costs and we expect to incur
additional costs related to becoming a public company, including
additional directors and officers liability
insurance, outside director compensation, additional personnel costs and the Sarbanes-Oxley Act of
2002 (Sarbanes-Oxley) and other compliance costs.
Our development and engineering expense, sales, marketing, general and administrative expense
and our corporate expense, while related to our current operations, are also affected and
influenced by our future plans (including the development of new products and services), business
strategies and enhancement and maintenance of our infrastructure.
Significant Items Affecting Comparability
Certain significant items or events should be considered to better understand differences in
our results of operations from period to period. We believe that the following items or events have
had a significant impact on our results of operations for the periods discussed below or may have a
significant impact on our results of operations in future periods:
Public Company Expenses
In August 2009, we completed an IPO of shares of our Class A common stock and our shares are
listed for trading on the New York Stock Exchange. As a result, we
now are required to comply with laws,
regulations and requirements that we previously were not required to comply with as a private company, including
provisions of Sarbanes-Oxley, other applicable SEC regulations and the requirements of the New York
32
Stock Exchange. Compliance with the requirements of being a public company will require us to
increase our general and administrative expenses in order to pay our employees, legal counsel and
independent registered public accountants to assist us in, among other things, instituting and
monitoring a more comprehensive compliance and board governance function, establishing and
maintaining internal control over financial reporting in accordance with Section 404 of
Sarbanes-Oxley and preparing and distributing periodic public reports in compliance with our obligations under the federal securities laws.
In addition, as a public company, it will be more expensive for us to maintain directors and
officers liability insurance.
Efficiency Measures
We evaluate and implement efficiency measures and other cost savings initiatives on an ongoing
basis to improve our financial and operating performance through cost savings, productivity
improvements and other process improvements. Since late 2006, we have increased these activities
and have initiated numerous measures to streamline our operations through innovation, integration
and consolidation. For instance, we are consolidating our data centers, consolidating our networks,
improving utilization of our existing data communication capabilities and outsourcing certain
information technology and operations functions. The implementation of these measures often involve
upfront costs related to severance, professional fees and/or contractor costs, with the cost
savings or other improvements not realized until the measures are successfully completed.
Long-term Debt
In connection with the 2006 Transaction, we borrowed an aggregate of $925.0 million under our
credit agreements for which we pay interest at a variable interest rate. In order to manage our
exposure to fluctuations in this interest rate, we executed an interest rate swap agreement in 2006
which has the effect of converting a portion of this obligation to a fixed rate of interest. At
its inception, we designated this interest rate swap agreement as a hedge of variability in our
cash flows such that changes in the value of this instrument were reflected within accumulated
comprehensive income. In connection with the 2008 Transaction, this instrument no longer met the
criteria for hedge accounting such that changes in its value from the date of the 2008 Transaction
to its redesignation as a hedge in September 2008 were reflected within interest expense. For the
nine months ended September 30, 2008, interest expense was reduced by $12.7 million due to changes
in the fair value of the interest rate swap agreement.
Income Taxes
Our
statutory federal and state income tax rate is approximately 40%. Several factors, such
as valuation allowance changes and changes in the book and income tax basis difference for accounting of our investment
in EBS Master, however, can affect the Companys effective tax rate for particular periods.
Related to the valuation allowance changes, during the nine months ended September 30, 2009,
we concluded, based primarily on our taxable income during the period and the expected accretive
impact of our recent acquisitions on future taxable income, that we would generate sufficient
future taxable income to utilize certain of our federal net operating losses, the benefit of which
we had not previously recognized. As a result, income tax expense for the three and nine month
periods ended September 30, 2009 is net of a benefit of approximately $0.0 million and $11.8
million, respectively, related to these net operating losses that had been the subject of a
valuation allowance in the comparable prior year periods. The benefit was partially offset by an
increase in state income tax valuation allowance during the nine
month period ended September 30, 2009 related to a consolidated subsidiary of
approximately $3.7 million.
Related to the changes in our basis in EBS Master, our book basis in EBS Master
changes based on equity-based compensation expense, as well as activity in other comprehensive
income (primarily related to our interest rate swap agreement).
These changes, however, do not affect our tax basis in EBS Master. As a result, these
changes in our book basis create deferred income taxes. Changes in equity-based compensation
expense during the three and nine month periods ended September 30, 2009 exceeded such changes in the
three and nine month periods ended September 30, 2008 by
approximately $10.8 million and $23.5 million, respectively,
primarily due to our
IPO. Changes in other comprehensive income during the three and nine
month periods ended September 30,
2009 exceeded such changes in the three and nine month periods ended
September 30, 2008 by approximately $0.2 million
and $10.8 million, respectively.
Changes in our operations also may cause our apportioned state income tax rate to change from
period to period. Such rate changes may require adjustment to our existing deferred income tax
assets and liabilities that have been recorded primarily as a result of our
33
investment in EBS
Master, as well as the 2006 Transaction and 2008 Transaction. A
change in our estimated state tax rate
resulted in additional deferred income taxes of approximately $1.5 million during the three month period ended
September 30, 2009.
Stock-Based and Equity-Based Compensation Expense
Prior
to the IPO, certain of our employees and directors participated in one of two
equity-based compensation plansthe Amended and Restated EBS Executive Equity Incentive Plan (the
EBS Equity Plan) and the Amended and Restated EBS Incentive Plan (the EBS Phantom Plan). In connection with the IPO, outstanding awards under the EBS
Phantom Plan were converted into awards under the 2009 Equity Incentive Plan adopted by the
Companys stockholders in July 2009 (the 2009 Plan) and outstanding awards under the EBS Equity
Plan were converted into EBS Units that are governed by individual agreements with certain
directors and members of executive management, as well as awards under the 2009 Plan. The EBS
Equity Plan consisted of a class of non-voting EBS Master equity units called Grant Units. The
Grant Units represented profits interests in EBS Master and appreciated with increases in value of
EBS Master. The EBS Phantom Plan was designed to allow individual employees to participate
economically in the future growth and value creation at EBS LLC. Each participant received a
specified number of units in the EBS Phantom Plan called Phantom Units. These Phantom Units
appreciated with increases in value of EBS Master. These Phantom Units did not give employees an
ownership interest in the Company and had no voting rights.
We incurred stock-based and equity-based compensation expense of $12.6 million and $0.7
million during the three months ended September 30, 2009 and
September 30, 2008, respectively, and
$21.5 million and $5.8 million during the nine months ended
September 30, 2009 and September 30,
2008, respectively. Comparability among the respective periods has been impacted by the following
factors:
|
|
|
Change in the estimated fair value of liability awards. All equity-based awards
granted under the EBS Equity Plan and EBS Phantom Plan prior to the second quarter of
2009 were classified as liabilities due to certain repurchase features. As liabilities,
we were required to adjust the equity-based awards to fair value at the end of each
quarter. The fair value of these liabilities generally fluctuated with the value of the
underlying EBS Units. |
|
|
|
Modification of equity-based awards. In June 2009, we modified the repurchase
features of all Grant Units previously granted under the EBS Equity Plan. Following this
modification, all Grant Units were reclassified as equity awards. Immediately prior to
this reclassification, we adjusted the value of these Grant Units to their fair value and
recognized equity-based compensation expense from this change in estimate of
approximately $4.6 million during the nine months ended September 30, 2009. |
|
|
|
Conversion in connection with our IPO. In connection with the IPO and reorganization
transactions, the Phantom Units were converted into 349,166 shares of our Class A common
stock, 733,598 restricted Class A common stock units and
1,401,736 options to purchase
shares of our Class A common stock. As a result of the IPO and this conversion, we
recognized equity-based compensation expense from this change in estimate of
approximately $9.2 million during the three and nine month periods ended September 30,
2009. |
|
|
|
Grant of options. On the IPO date, we also granted options to purchase 652,000 shares
of our Class A common stock to certain of our employees and
directors. |
Critical Accounting Policies
We prepare our consolidated financial statements in accordance with accounting principles
generally accepted in the United States. The preparation of these consolidated financial statements
requires us to make estimates and assumptions that affect the reported amounts of assets,
liabilities, revenue, expense and related disclosures. We base our estimates and assumptions on the
best information available to us at the time the estimates and assumptions are made, on historical
experience and on various other factors that we believe to be reasonable under the circumstances.
We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from
these estimates under different assumptions or conditions.
We believe the following critical accounting policies include areas that require a significant
amount of judgment and estimates.
34
Revenue Recognition
We generate revenues by providing products and services that automate and simplify business
and administrative functions for payers and providers, generally on either a per transaction, per
document, per communication basis or, in some cases, on a monthly flat-fee basis. We generally
charge a one-time implementation fee to payers and providers at the inception of a contract in
connection with related setup and connection to our network and other systems. In addition, we
receive software license fees and software and hardware maintenance fees from payers who license
our systems for converting paper claims into electronic claims and, occasionally, sell additional
software and hardware products to such payers.
Revenue for transaction services, payment services and patient statements are recognized as
the services are provided. Postage fees related to our payment services and patient statement
volumes are recorded on a gross basis in accordance with Financial Accounting Standards Board
(FASB) Accounting Standards Codification (ASC) Revenue Recognition Topic (Principal Agent
Considerations Subtopic). Implementation and software license and software maintenance fees are
amortized to revenue on a straight-line basis over the contract period, which generally varies from
one to three years. Software and hardware sales are recognized once all elements are delivered and
customer acceptance is received.
Cash receipts or billings in advance of revenue recognition are recorded as deferred revenues
on our consolidated balance sheets.
We exclude sales and use tax from revenue in our consolidated statements of operations.
Software Development Costs
We account for internal use software development costs in accordance with the FASB ASC
IntangiblesGoodwill and Other Topic (Internal Use Software Subtopic). Software development costs
that are incurred in the preliminary project stage are expensed as incurred. Once certain criteria
have been met, direct costs incurred in developing or obtaining computer software are capitalized.
Training and data conversion costs are expensed as incurred. Capitalized software costs are
included in property and equipment within our consolidated balance sheets and are amortized over a
three-year period.
Business Combinations
In accordance with the FASB ASC Business Combinations Topic, we allocate the consideration
transferred (i.e. purchase price) in a business combination to the acquired business identifiable
assets, liabilities and noncontrolling interests at their acquisition date fair value. The excess
of the purchase price over the amount allocated to the identifiable assets, liabilities and
noncontrolling interests, if any, is recorded as goodwill. Any excess of fair value of the
identifiable assets acquired and liabilities assumed over the consideration transferred, if any, is
generally recognized within our earnings as of the acquisition date.
We estimate the fair value of the assets, liabilities and noncontrolling interests based on
one or a combination of income, cost, or market approaches as determined based on the nature of the
asset or liability and the level of inputs available to us (i.e. quoted prices in an active market,
other observable inputs or unobservable inputs). To the extent that our initial accounting for a
business combination is incomplete at the end of a reporting period, we report provisional amounts
for those items which are incomplete. We retroactively adjust such provisional amounts as of the
acquisition date once we receive new information about facts and circumstances that existed as of
the acquisition date.
Goodwill and Intangible Assets
Goodwill and intangible assets from our acquisitions are accounted for using the acquisition
method of accounting. Intangible assets with definite lives are amortized on a straight-line basis
over the estimated useful lives of the related assets generally as follows:
|
|
|
|
|
Customer relationships |
|
9 to 20 years |
Trade names |
|
20 years |
Non-compete agreements |
|
1 to 5 years |
In accordance with the FASB ASC IntangiblesGoodwill and Other Topic, we review the carrying
value of goodwill annually and whenever indicators of impairment are present. With respect to
goodwill, we determine whether potential impairment losses are
35
present by comparing the carrying
value of our reporting units to the fair value of our reporting units. If the fair value of the
reporting unit is less than the carrying value of the reporting unit, then a hypothetical purchase price
allocation is used to determine the amount of goodwill impairment.
We have identified our payer, provider and pharmacy operating segments as our reporting units.
We estimate the fair value of our reporting units using a methodology that considers both income
and market approaches. Specifically, we develop an initial estimate of the fair value of each
reporting unit as the present value of the expected future cash flows to be generated by the
reporting unit. We then validate this initial amount by comparison to a value determined based on
transaction multiples among guideline publicly traded companies.
Each approach requires the use of certain assumptions. The income approach requires management
to exercise judgment in making assumptions regarding the reporting units future income stream, a
discount rate and a constant rate of growth after the initial five year forecast period utilized.
These assumptions are subject to change based on business and economic conditions and could
materially affect the indicated values of our reporting units. For example, a 100 basis point
change in our selected discount rate would result in a change in the indicated value of our payer,
provider and pharmacy reporting units of approximately $91.1 million, $97.5 million and $12.6
million, respectively, which would have required an additional impairment analysis.
The market approach requires management to exercise judgment in its selection of the guideline
companies, as well in its selection of the most relevant transaction multiple. Guideline companies
selected are comparable to us in terms of product or service offerings, markets and/or customers,
among other characteristics. We considered two transaction multiples (i) the ratio of market
value of invested capital to earnings before interest and taxes (MVIC/EBIT) and (ii) the ratio of
market value of invested capital to earnings before interest, taxes, depreciation, and amortization
(MVIC/EBITDA).
Our method of assessing the fair value of our reporting units and our method of selecting the
key assumptions did not change from 2007 to 2008. However, a decline in the market returns on
equity and the borrowing costs at the date of our evaluation resulted
in an average 200 basis point
decrease in the discount rate as compared to the prior year discount rate.
Income Taxes
We account for income taxes under the provisions of the FASB ASC Income Taxes Topic. We are
generally required to record deferred income taxes for the tax effect of differences between book
and tax bases of our assets and liabilities.
Deferred income taxes reflect the available net operating losses and the net tax effect of
temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Realization of the future tax
benefits related to deferred tax assets is dependent on many factors, including our past earnings
history, expected future earnings, the character and jurisdiction of such earnings, unsettled
circumstances that, if unfavorably resolved would adversely affect utilization of our deferred tax
assets, carryback and carryforward periods, and tax strategies that could potentially enhance the
likelihood of realization of a deferred tax asset.
We also recognize uncertain tax positions in accordance with the FASB ASC Income Taxes Topic,
which prescribes a recognition threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken in a tax return.
Equity-Based Compensation
Compensation expense related to our equity-based awards is recognized on a straight-line basis
over the vesting period under the provisions of the FASB ASC Compensation Topic (Stock Compensation
Subtopic) using the modified prospective method. The fair value of equity awards is determined by
use of a Black-Scholes model and assumptions as to expected term, expected volatility, expected
dividends and the risk free rate.
36
Tax Receivable Agreements
In
connection with the IPO, we entered into tax receivable agreements which obligate
us to make payments to certain parties affiliated with General
Atlantic and H&F and former
Grant Unit holders generally equal to 85% of the applicable cash
savings that we realize
as a result of tax attributes arising from the 2006 Transaction, the
2008 Transaction and exchanges of EBS Units for cash or shares of
Class A common stock. We will retain the benefit of the
remaining 15% of these tax savings.
We estimate that these payments will total approximately $141.7
million over the life of the tax receivable agreements with payments
expected to begin during 2011.
All future exchanges of EBS Units for cash or shares of Class A common stock related to the
affiliates of H&F and the former Grant Unit holders who are parties to the tax
receivable agreements are expected to result in an additional tax
receivable obligation for us with a corresponding offset to our additional paid in capital account. Subsequent
adjustments of the tax receivable obligations due to certain events (e.g. realization of net
operating losses, tax rate changes or the timing of cash settlement obligations) are expected to
result in a corresponding adjustment of our net income.
37
Results of Operations
The following table summarizes our unaudited condensed consolidated results of operations
for the three and nine month periods ended September 30, 2008 and September 30, 2009 (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, 2008 |
|
|
September 30, 2009 |
|
|
September 30, 2008 |
|
|
September 30, 2009 |
|
|
|
|
|
|
|
% of |
|
|
|
|
|
|
% of |
|
|
|
|
|
|
% of |
|
|
|
|
|
|
% of |
|
|
|
Amount |
|
|
Revenue (1) |
|
|
Amount |
|
|
Revenue (1) |
|
|
Amount |
|
|
Revenue (1) |
|
|
Amount |
|
|
Revenue (1) |
|
Revenues (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payer Services |
|
$ |
92,842 |
|
|
|
43.6 |
% |
|
$ |
99,714 |
|
|
|
42.3 |
% |
|
$ |
277,441 |
|
|
|
43.6 |
% |
|
$ |
294,307 |
|
|
|
43.3 |
% |
Provider Services |
|
|
110,986 |
|
|
|
52.2 |
|
|
|
117,275 |
|
|
|
49.8 |
|
|
|
330,979 |
|
|
|
52.1 |
|
|
|
347,207 |
|
|
|
51.1 |
|
Pharmacy Services |
|
|
9,569 |
|
|
|
4.5 |
|
|
|
19,186 |
|
|
|
8.1 |
|
|
|
29,191 |
|
|
|
4.6 |
|
|
|
40,196 |
|
|
|
5.9 |
|
Eliminations |
|
|
(589 |
) |
|
|
(0.3 |
) |
|
|
(713 |
) |
|
|
(0.3 |
) |
|
|
(1,945 |
) |
|
|
(0.3 |
) |
|
|
(1,822 |
) |
|
|
(0.3 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
212,808 |
|
|
|
100.0 |
|
|
|
235,462 |
|
|
|
100.0 |
|
|
|
635,666 |
|
|
|
100.0 |
|
|
|
679,888 |
|
|
|
100.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs of operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payer Services |
|
|
60,528 |
|
|
|
65.2 |
|
|
|
65,805 |
|
|
|
66.0 |
|
|
|
182,838 |
|
|
|
65.9 |
|
|
|
188,094 |
|
|
|
63.9 |
|
Provider Services |
|
|
72,546 |
|
|
|
65.4 |
|
|
|
75,070 |
|
|
|
64.0 |
|
|
|
218,311 |
|
|
|
66.0 |
|
|
|
221,464 |
|
|
|
63.8 |
|
Pharmacy Services |
|
|
1,816 |
|
|
|
19.0 |
|
|
|
6,158 |
|
|
|
32.1 |
|
|
|
5,687 |
|
|
|
19.5 |
|
|
|
9,947 |
|
|
|
24.7 |
|
Eliminations |
|
|
(439 |
) |
|
|
|
|
|
|
(562 |
) |
|
|
|
|
|
|
(1,413 |
) |
|
|
|
|
|
|
(1,426 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs of operations |
|
|
134,451 |
|
|
|
63.2 |
|
|
|
146,471 |
|
|
|
62.2 |
|
|
|
405,423 |
|
|
|
63.8 |
|
|
|
418,079 |
|
|
|
61.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Development and engineering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payer Services |
|
|
2,655 |
|
|
|
2.9 |
|
|
|
3,847 |
|
|
|
3.9 |
|
|
|
7,453 |
|
|
|
2.7 |
|
|
|
9,172 |
|
|
|
3.1 |
|
Provider Services |
|
|
3,608 |
|
|
|
3.3 |
|
|
|
4,297 |
|
|
|
3.7 |
|
|
|
10,472 |
|
|
|
3.2 |
|
|
|
11,283 |
|
|
|
3.2 |
|
Pharmacy Services |
|
|
1,049 |
|
|
|
11.0 |
|
|
|
1,901 |
|
|
|
9.9 |
|
|
|
3,104 |
|
|
|
10.6 |
|
|
|
3,970 |
|
|
|
9.9 |
|
Eliminations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total development and engineering |
|
|
7,312 |
|
|
|
3.4 |
|
|
|
10,045 |
|
|
|
4.3 |
|
|
|
21,029 |
|
|
|
3.3 |
|
|
|
24,425 |
|
|
|
3.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales, marketing, general and admin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payer Services |
|
|
6,004 |
|
|
|
6.5 |
|
|
|
8,037 |
|
|
|
8.1 |
|
|
|
18,727 |
|
|
|
6.7 |
|
|
|
20,461 |
|
|
|
7.0 |
|
Provider Services |
|
|
7,136 |
|
|
|
6.4 |
|
|
|
9,038 |
|
|
|
7.7 |
|
|
|
22,888 |
|
|
|
6.9 |
|
|
|
24,335 |
|
|
|
7.0 |
|
Pharmacy Services |
|
|
1,002 |
|
|
|
10.5 |
|
|
|
3,413 |
|
|
|
17.8 |
|
|
|
2,896 |
|
|
|
9.9 |
|
|
|
5,439 |
|
|
|
13.5 |
|
Eliminations |
|
|
(193 |
) |
|
|
|
|
|
|
(151 |
) |
|
|
|
|
|
|
(527 |
) |
|
|
|
|
|
|
(398 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total sales, marketing, general
and admin excluding corporate |
|
|
13,949 |
|
|
|
6.6 |
|
|
|
20,337 |
|
|
|
8.6 |
|
|
|
43,984 |
|
|
|
6.9 |
|
|
|
49,837 |
|
|
|
7.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from segment operations |
|
|
57,096 |
|
|
|
26.8 |
|
|
|
58,609 |
|
|
|
24.9 |
|
|
|
165,230 |
|
|
|
26.0 |
|
|
|
187,547 |
|
|
|
27.6 |
|
Corporate expense |
|
|
8,271 |
|
|
|
3.9 |
|
|
|
13,968 |
|
|
|
5.9 |
|
|
|
25,325 |
|
|
|
4.0 |
|
|
|
36,051 |
|
|
|
5.3 |
|
Depreciation and amortization |
|
|
25,710 |
|
|
|
12.1 |
|
|
|
26,667 |
|
|
|
11.3 |
|
|
|
71,979 |
|
|
|
11.3 |
|
|
|
77,051 |
|
|
|
11.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
|
23,115 |
|
|
|
10.9 |
|
|
|
17,974 |
|
|
|
7.6 |
|
|
|
67,926 |
|
|
|
10.7 |
|
|
|
74,445 |
|
|
|
10.9 |
|
Interest income |
|
|
(328 |
) |
|
|
(0.2 |
) |
|
|
(27 |
) |
|
|
(0.0 |
) |
|
|
(931 |
) |
|
|
(0.1 |
) |
|
|
(81 |
) |
|
|
(0.0 |
) |
Interest expense |
|
|
20,410 |
|
|
|
9.6 |
|
|
|
17,219 |
|
|
|
7.3 |
|
|
|
49,899 |
|
|
|
7.8 |
|
|
|
52,330 |
|
|
|
7.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income tax provision |
|
|
3,033 |
|
|
|
1.4 |
|
|
|
782 |
|
|
|
0.3 |
|
|
|
18,958 |
|
|
|
3.0 |
|
|
|
22,196 |
|
|
|
3.3 |
|
Income tax provision |
|
|
3,512 |
|
|
|
1.7 |
|
|
|
9,245 |
|
|
|
3.9 |
|
|
|
11,202 |
|
|
|
1.8 |
|
|
|
12,885 |
|
|
|
1.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
(479 |
) |
|
|
(0.2 |
)% |
|
|
(8,463 |
) |
|
|
(3.6 |
)% |
|
|
7,756 |
|
|
|
1.2 |
% |
|
|
9,311 |
|
|
|
1.4 |
% |
Net income (loss) attributable to
noncontrolling interest |
|
|
766 |
|
|
|
|
|
|
|
(1,246 |
) |
|
|
|
|
|
|
2,620 |
|
|
|
|
|
|
|
2,871 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to
Emdeon Inc. |
|
$ |
(1,245 |
) |
|
|
|
|
|
$ |
(7,217 |
) |
|
|
|
|
|
$ |
5,136 |
|
|
|
|
|
|
$ |
6,440 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
All references to percentage of revenues for expense components refer to the percentage of
revenues for such segment. |
|
(2) |
|
See Note 16-Segment Reporting to our unaudited condensed consolidated financial statements
for further detail of our revenues within each reportable segment. |
38
Three
Months Ended September 30, 2009 Compared to Three Months Ended
September 30, 2008
Revenues
Our total revenues were $235.5 million for the three months ended September 30, 2009 as
compared to $212.8 million for the three months ended September 30, 2008, an increase of
approximately $22.7 million, or 10.6%.
Our payer services segment revenue is summarized by product line in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30. |
|
September 30, |
|
|
|
|
2009 |
|
2008 |
|
$ Change |
Claims management |
|
$ |
46,072 |
|
|
$ |
44,066 |
|
|
$ |
2,006 |
|
Payment services |
|
|
53,345 |
|
|
|
48,699 |
|
|
|
4,646 |
|
Intersegment revenue |
|
|
297 |
|
|
|
77 |
|
|
|
220 |
|
|
|
|
|
|
$ |
99,714 |
|
|
$ |
92,842 |
|
|
$ |
6,872 |
|
|
|
|
Claims management revenues for the three months ended September 30, 2009 increased by
approximately $2.0 million, or 4.6%, from the three months ended September 30, 2008 primarily due
to an increase in the volume of electronic claims processed during the current year period, as well
as $0.9 million of payment integrity solutions generated following our acquisition of the Sentinel
Group in June 2009. Payment services revenues for the three months ended September 30, 2009
increased by approximately $4.6 million, or 9.5%. This increase was primarily driven by new sales
and implementations, as well as the impact of the U.S. postage rate increase effective in May 2009.
Our provider services segment revenue is summarized by product line in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
September 30, |
|
|
|
|
2009 |
|
2008 |
|
$ Change |
Patient statements |
|
$ |
69,840 |
|
|
$ |
66,279 |
|
|
$ |
3,561 |
|
Revenue cycle management |
|
|
39,041 |
|
|
|
36,256 |
|
|
|
2,785 |
|
Dental |
|
|
7,978 |
|
|
|
7,939 |
|
|
|
39 |
|
Intersegment revenue |
|
|
416 |
|
|
|
512 |
|
|
|
(96 |
) |
|
|
|
|
|
$ |
117,275 |
|
|
$ |
110,986 |
|
|
$ |
6,289 |
|
|
|
|
Patient statement revenues for the three months ended September 30, 2009 increased
approximately $3.6 million, or 5.4%, primarily due to the acquisition of the patient statement
business of GE Healthcare Information Technology (the GE Patient Statement Acquisition) in
September 2008 and the impact of the U.S. postage rate increase effective in May 2009, partially
offset by customer attrition. Revenue cycle management revenues for the three months ended
September 30, 2009 increased approximately $2.8 million, or 7.7%, primarily from new sales and
implementations, partially offset by attrition in legacy products. Dental revenues for the three
months ended September 30, 2009 were generally consistent with those reflected in the comparable
prior year period.
Our pharmacy services segment revenues were $19.2 million for the three months ended September
30, 2009 as compared to $9.6 million for the three months ended September 30, 2008, an increase of
approximately $9.6 million, or 100.0%. This increase was primarily due to our acquisition of eRx on
July 2, 2009, as well as new sales and implementations.
Cost of Operations
Our total cost of operations was $146.5 million for the three months ended September 30, 2009
as compared to $134.5 million for the three months ended September 30, 2008, an increase of
approximately $12.0 million, or 8.9%.
Our cost of operations for our payer services segment was approximately $65.8 million for the
three months ended September 30, 2009 as compared to $60.5 million for the three months ended
September 30, 2008, an increase of approximately $5.3 million, or 8.7%. As a percentage of revenue,
our payer services costs of operations increased to 66.0% for the three months ended September 30,
2009 as compared to 65.2% for the three months ended September 30, 2008. Costs of operations for
our payer services segment
39
includes approximately $2.6 million and $0.1 million of equity-based
compensation for the three months ended September 30, 2009 and September 30, 2008, respectively.
Excluding this equity-based compensation, payer services cost of operations were $63.3 million for
the three months ended September 30, 2009 as compared to $60.4 million for the three months ended
September 30, 2008, an increase of approximately $2.8 million, or 4.7%. The increase is primarily
due to revenue growth in payment services, including increased postage costs resulting from the
U.S. postage rate increase effective in May 2009, which was partially offset by reduced data
communication expenses from improved utilization of our existing data communication capabilities.
Excluding the equity-based compensation, as a percentage of revenue, our payer services costs of
operations decreased to 63.4% for the three months ended September 30, 2009 as compared to 65.1%
for the three months ended September 30, 2008. This decrease was primarily due to reduced data
communication expenses and production efficiencies in our payment services business.
Our cost of operations for our provider services segment was $75.1 million for the three
months ended September 30, 2009 as compared to $72.5 million for the three months ended September
30, 2008, an increase of approximately $2.5 million, or 3.5%. As a percentage of revenue, our
provider services segment costs of operations decreased to 64.0% for the three months ended
September 30, 2009 as compared to 65.4% for the three months ended September 30, 2008. Costs of
operations for our provider services segment includes approximately $1.7 million and $0.0 million
related to equity-based compensation for the three months ended September 30, 2009 and September
30, 2008, respectively. Excluding this equity-based compensation, provider services costs of
operations were $73.3 million for the three months ended September 30, 2009 as compared to $72.5
million for the three months ended September 30, 2008, an increase of approximately $0.8 million,
or 1.1%. The increase is primarily due to revenue growth, partially offset by reduced
data communication expenses from improved utilization of our existing data communication
capabilities. Excluding the equity-based compensation, as a percentage of revenue, our provider
services costs of operations decreased to 62.5% for the three months ended September 30, 2009 as
compared to 65.3% for the three months ended September 30, 2008. This decrease was primarily due
to reduced data communication expenses, efficiency measures related to facility consolidations in
our patient statement operations and higher revenue growth rates in our revenue cycle management
solutions, which typically have higher margins than our other provider services solutions.
Our cost of operations for our pharmacy services segment was $6.2 million for the three months
ended September 30, 2009 as compared to $1.8 million for the three months ended September 30, 2008,
an increase of $4.3 million, or 239.1%. This increase is primarily related to the inclusion of the
revenues and associated costs of the eRx business following our acquisition of eRx on July 2, 2009.
Development and Engineering Expense
Our total development and engineering expense was $10.0 million for the three months ended
September 30, 2009 as compared to $7.3 million for the three months ended September 30, 2008, an
increase of approximately $2.7 million, or 37.4%. Development and engineering expense includes
approximately $0.9 million and $0.0 million related to equity-based compensation for the three
months ended September 30, 2009 and September 30, 2008, respectively. Excluding this equity-based
compensation, development and engineering expense was $9.1 million for the three months ended
September 30, 2009 as compared to $7.3 million for the three months ended September 30, 2008, an
increase of approximately $1.8 million, or 25.0%. This increase is primarily related to increased product development activity in the three months ended September 30, 2009 and the
inclusion of the product development infrastructure associated with our acquisition of eRx on July
2, 2009, which is presently being integrated with our historical pharmacy services infrastructure.
Sales, Marketing, General and Administrative Expense (Excluding Corporate Expense)
Our total sales, marketing, general and administrative expense (excluding corporate expense)
was $20.3 million for the three months ended September 30, 2009 as compared to $13.9 million for
the three months ended September 30, 2008, an increase of approximately $6.4 million, or 45.8%.
Our sales, marketing, general and administrative expense for our payer services segment was
$8.0 million for the three months ended September 30, 2009 as compared to $6.0 million for the
three months ended September 30, 2008, an increase of approximately $2.0 million, or 33.9%. Sales,
marketing, general and administrative expense for our payer services segment includes approximately
$2.1 million and $0.2 million related to equity-based compensation for the three months ended
September 30, 2009 and September 30,
40
2008, respectively. Excluding this equity-based compensation,
payer services sales,
marketing, general and administrative expense was $5.9 million for the three months ended September 30, 2009
as compared to $5.8 million for the three months ended September 30, 2008, an increase of
approximately $0.1 million, or 2.4%.
Our sales, marketing, general and administrative expense for our provider services segment was
$9.0 million for the three months ended September 30, 2009 as compared to $7.1 million for the
three months ended September 30, 2008, an increase of approximately $1.9 million, or 26.7%. Sales,
marketing, general and administrative expense for our provider services segment includes
approximately $2.0 million and $0.1 million related to equity-based compensation for the three
months ended September 30, 2009 and September 30, 2008, respectively. Excluding this equity-based
compensation, provider services sales, marketing, general and administrative expense was $7.1
million for the three months ended September 30, 2009 as compared to $7.0 million for the three
months ended September 30, 2008, an increase of approximately $0.1 million, or 1.4%.
Our sales, marketing, general and administrative expense for our pharmacy services segment was
approximately $3.4 million for the three months ended September 30, 2009 as compared to $1.0
million for the three months ended September 30, 2008, an increase of approximately $2.4 million,
or 240.6%. Sales, marketing, general and administrative expense for our pharmacy services segment
includes approximately $0.4 million and $0.0 million related to equity-based compensation for the
three months ended September 30, 2009 and September 30, 2008, respectively. Excluding this
equity-based compensation, pharmacy services sales, marketing, general and administrative expense
was $3.1 million for the three months ended September 30, 2009 as compared to $1.0 million for the
three months ended September 30, 2008, an increase of approximately $2.1 million, or 206.7%. This
increase is primarily related to the inclusion of the infrastructure associated with our
acquisition of eRx on July 2, 2009, which is presently being integrated with our historical
pharmacy services infrastructure.
Corporate Expense
Our corporate expense was $14.0 million for the three months ended September 30, 2009 as
compared to $8.3 million for the three months ended September 30, 2008, an increase of
approximately $5.7 million, or 68.9%. Corporate expense includes approximately $2.8 million and
$0.3 million related to equity-based compensation for the three months ended September 30, 2009 and
September 30, 2008, respectively. Excluding this equity-based compensation, corporate expense was
$11.2 million for the three months ended September 30, 2009 as compared to $7.9 million for the
three months ended September 30, 2008, an increase of approximately $3.2 million, or 40.4%. The
increase in the current year period was primarily due to (i) incremental costs associated with
building the infrastructure required to operate as a public company,
such as increased directors
and officers liability insurance costs, increased compliance costs and additional
finance, legal and other personnel costs, (ii) expenses associated with the IPO (including the costs of related
amendments to our credit agreements) and (iii) costs of added corporate functions, including
business development and public relations, not included in the prior year period.
Depreciation and Amortization Expense
Our depreciation and amortization expense was $26.7 million for the three months ended
September 30, 2009 as compared to $25.7 million for the three months ended September 30, 2008, an
increase of approximately $1.0 million, or 3.7%. This increase was primarily due to depreciation of
property and equipment placed in service subsequent to September 30, 2008, as well as additional
depreciation and amortization expense related to purchase accounting adjustments associated with
the eRx acquisition and GE Patient Statement Acquisition in July 2009 and September 2008, respectively.
Interest Income
We had minimal interest income for the three months ended September 30, 2009 as compared to
$0.3 million for the three months ended September 30, 2008, a decrease of approximately $0.3
million. While our interest-bearing cash and cash equivalent balances have increased since
September 30, 2008, this increase was more than offset by the effect of a reduction in the market
interest rates available to us during the three months ended September 30, 2009.
41
Interest Expense
Our interest expense was $17.2 million for the three months ended September 30, 2009 as
compared to $20.4 million for the three months ended September 30, 2008, a decrease of
approximately $3.2 million, or 15.6%. This decrease is primarily due to a scheduled decrease in
the notional amount of our interest rate swap of approximately $175.1 million that occurred on
December 31, 2008, offset by a difference in the periods for which our interest rate swap was
designated as a hedge for accounting purposes. The decrease in the notional amount of our interest
rate swap agreement caused interest expense to decline because the fixed rate we paid during the
three months ended September 30, 2009 under the interest rate swap exceeded the interest rate on
our term loans so that less of our debt was subject to this higher fixed rate. Our notional amount
is further scheduled to decrease by an additional $123.6 million on December 31, 2009.
Our discontinuation of hedge accounting treatment in 2008 required us to adjust our interest
rate swap to fair market value with the change reflected in interest expense. The three months
ended September 30, 2008 included a reduction of interest expense of approximately $0.9 million
related to this fair value adjustment. No similar adjustment was reflected in the three months
ended September 30, 2009 as we redesignated our interest rate swap agreement as a hedge of our
interest rate risk in September 2008.
Income Taxes
Our income tax expense was $9.2 million for the three months ended September 30, 2009 as
compared to $3.5 million for the three months ended September 30, 2008, an increase of
approximately $5.7 million, or 163.2%. Differences between the federal statutory rate and the
effective income tax rates for these periods principally relate to the change in our book basis
versus tax basis in our investment in EBS Master, including the effect of income allocated to a
noncontrolling interest, valuation allowance changes, state income tax rate changes and the impact
of other permanent differences relative to pre-tax income.
Nine Months Ended September 30, 2009 Compared to Nine Months Ended September 30, 2008
Revenues
Our total revenues were $679.9 million for the nine months ended September 30, 2009 as
compared to $635.7 million for the nine months ended September 30, 2008, an increase of
approximately $44.2 million, or 7.0%.
Our payer services segment revenue is summarized by product line in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
September 30, |
|
|
|
|
2009 |
|
2008 |
|
$ Change |
Claims management |
|
$ |
137,440 |
|
|
$ |
134,621 |
|
|
$ |
2,819 |
|
Payment services |
|
|
156,433 |
|
|
|
142,522 |
|
|
|
13,911 |
|
Intersegment revenue |
|
|
434 |
|
|
|
298 |
|
|
|
136 |
|
|
|
|
|
|
$ |
294,307 |
|
|
$ |
277,441 |
|
|
$ |
16,866 |
|
|
|
|
Claims management revenues for the nine months ended September 30, 2009 increased by
approximately $2.8 million, or 2.1%, from the nine months ended September 30, 2008 primarily due to
an increase in the volume of electronic claims processed during the current year period, as well as
$1.1 million of payment integrity solutions generated following our acquisition of the Sentinel
Group in June 2009. Payment services revenues for the nine months ended September 30, 2009
increased by approximately $13.9 million, or 9.8%. This increase was primarily driven by new sales
and implementations, as well as the impact of U.S. postage rate increases effective in May 2008 and
May 2009.
Our provider services segment revenue is summarized by product line in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30 |
|
September 30, |
|
|
|
|
2009 |
|
2008 |
|
$ Change |
Patient statements |
|
$ |
207,304 |
|
|
$ |
198,500 |
|
|
$ |
8,804 |
|
Revenue cycle management |
|
|
114,825 |
|
|
|
106,894 |
|
|
|
7,931 |
|
Dental |
|
|
23,690 |
|
|
|
23,938 |
|
|
|
(248 |
) |
Intersegment revenue |
|
|
1,388 |
|
|
|
1,647 |
|
|
|
(259 |
) |
|
|
|
|
|
$ |
347,207 |
|
|
$ |
330,979 |
|
|
$ |
16,228 |
|
|
|
|
42
Patient statement revenues for the nine months ended September 30, 2009 increased
approximately $8.8 million, or 4.4%, primarily due to the GE Patient Statement acquisition in
September 2008 and the impact of U.S. postage rate increases effective in May 2008 and May 2009,
partially offset by customer attrition. Revenue cycle management revenues for the nine months ended
September 30, 2009 increased approximately $7.9 million, or 7.4%, primarily from new sales and
implementations, partially offset by attrition in legacy products. Dental revenues for the nine
months ended September 30, 2009 decreased approximately $0.2 million, or 1.0%, primarily due to
pricing pressures in the dental market.
Our pharmacy services segment revenues were $40.2 million for the nine months ended September
30, 2009 as compared to $29.2 million for the nine months ended September 30, 2008, an increase of
approximately $11.0 million, or 37.7%. This increase was primarily due to the acquisition of eRx in
July 2009, as well as new sales and implementations.
Cost of Operations
Our total cost of operations was $418.1 million for the nine months ended September 30, 2009
as compared to $405.4 million for the nine months ended September 30, 2008, an increase of
approximately $12.7 million, or 3.1%.
Our cost of operations for our payer services segment was approximately $188.1 million for the
nine months ended September 30, 2009 as compared to $182.8 million for the nine months ended
September 30, 2008, an increase of approximately $5.3 million, or 2.9%. As a percentage of revenue,
our payer services costs of operations decreased to 63.9% for the nine months ended September 30,
2009 as compared to 65.9% for the nine months ended September 30, 2008. Costs of operations for our
payer services segment includes approximately $3.8 million and $0.9 million related to equity-based
compensation for the nine months ended September 30, 2009 and September 30, 2008, respectively.
Excluding this equity-based compensation, payer services costs of operations were $184.3 million
for the three months ended September 30, 2009 as compared to $181.9 million for the nine months
ended September 30, 2008, an increase of approximately $2.4 million, or 1.3%. The increase is
primarily due to revenue growth in payment services, including increased postage costs resulting
from the U.S. postage rate increases effective in May 2008 and May 2009, which was partially offset
by (i) reduced data communication expenses from improved utilization of our existing data
communication capabilities, (ii) reduced rebates due to the expiration of two contracts with a
channel partner and (iii) the absence of severance costs related to 2008 efficiency measures
combined with the resulting reduction in compensation for the nine months ended September 30, 2009.
Excluding the equity-based compensation, as a percentage of revenue, our payer services costs of
operations decreased to 62.6% for the nine months ended September 30, 2009 as compared to 65.6% for
the nine months ended September 30, 2008. This decrease was primarily due to reduced data
communication expenses and production efficiencies in our payment services business.
Our cost of operations for our provider services segment was $221.5 million for the nine
months ended September 30, 2009 as compared to $218.3 million for the nine months ended September
30, 2008, an increase of approximately $3.2 million, or 1.4%. As a percentage of revenue, our
provider services segment costs of operations decreased to 63.8% for the nine months ended
September 30, 2009 as compared to 66.0% for the nine months ended September 30, 2008. Costs of
operations for our provider services segment includes approximately $2.0 million and $0.2 million
related to equity-based compensation for the nine months ended September 30, 2009 and September 30,
2008, respectively. Excluding this equity-based compensation, provider services costs of
operations were $219.5 million for the nine months ended September 30, 2009 as compared to $218.1
million for the nine months ended September 30, 2008, an increase of approximately $1.3 million, or
0.6%. The increase is primarily due to revenue growth, partially offset by reduced data communication
expenses from improved utilization of our existing data communication capabilities. Excluding the
equity-based compensation, as a percentage of revenue, our provider services costs of operations
decreased to 63.2% for the nine months ended September 30, 2009 as compared to 65.9% for the nine
months ended September 30, 2008. This decrease was primarily due to reduced data communication
expenses and higher revenue growth rates in our revenue cycle management solutions, which typically
have higher margins than our other provider services solutions.
Our cost of operations for our pharmacy services segment was $9.9 million for the nine months
ended September 30, 2009 as compared to $5.7 million for the nine months ended September 30, 2008,
an increase of $4.3 million, or 74.9%. This increase is primarily related to inclusion of the
revenues and associated costs of the eRx business following our acquisition of eRx on July 2, 2009.
43
Development and Engineering Expense
Our total development and engineering expense was $24.4 million for the nine months ended
September 30, 2009 as compared to $21.0 million for the nine months ended September 30, 2008, an
increase of approximately $3.4 million, or 16.2%. Development and engineering expense includes
approximately $1.0 million and $0.0 million related to equity-based compensation for the nine
months ended September 30, 2009 and September 30, 2008, respectively. Excluding this equity-based
compensation, development and engineering expense was $23.4 million for the nine months ended
September 30, 2009 as compared to $21.0 million for the nine months ended September 30, 2008, an
increase of approximately $2.5 million, or 11.7%. This increase is primarily related to increased product development
activity in the nine months ended September 30, 2009 and the
inclusion of the product development infrastructure associated with our acquisition of eRx on July
2, 2009, which is presently being integrated with our historical pharmacy services infrastructure.
Sales, Marketing, General and Administrative Expense (Excluding Corporate Expense)
Our total sales, marketing, general and administrative expense (excluding corporate expense)
was $49.8 million for the nine months ended September 30, 2009 as compared to $44.0 million for the
nine months ended September 30, 2008, an increase of approximately $5.9 million, or 13.3%.
Our sales, marketing, general and administrative expense for our payer services segment was
$20.5 million for the nine months ended September 30, 2009 as compared to $18.7 million for the
nine months ended September 30, 2008, an increase of approximately $1.7 million, or 9.3%. Sales,
marketing, general and administrative expense for our payer services segment includes approximately
$3.8 million and $1.4 million related to equity-based compensation for the nine months ended
September 30, 2009 and September 30, 2008, respectively. Excluding this equity-based compensation,
payer services sales, marketing, general and administrative expense was $16.6 million for the nine
months ended September 30, 2009 as compared to $17.4 million for the nine months ended September
30, 2008, a decrease of approximately $0.8 million, or 4.3%. This decrease was primarily due to
the absence in the nine month period ended September 30, 2009 of severance costs and compensation
related to 2008 efficiency measures.
Our sales, marketing, general and administrative expense for our provider services segment was
$24.3 million for the nine months ended September 30, 2009 as compared to $22.9 million for the
nine months ended September 30, 2008, an increase of approximately $1.4 million, or 6.3%. Sales,
marketing, general and administrative expense for our provider services segment includes
approximately $3.1 million and $1.0 million related to equity-based compensation for the nine
months ended September 30, 2009 and September 30, 2008, respectively. Excluding this equity-based
compensation, provider services sales, marketing, general and administrative expense was $21.3
million for the nine months ended September 30, 2009 as compared to $22.0 million for the nine
months ended September 30, 2008, a decrease of approximately 0.7 million, or 3.2%. This decrease
was primarily due to 2008 efficiency measures which reduced compensation costs, as well as our
utilization of internal personnel to develop product enhancements for which eligible costs were
capitalized in the nine months ended September 30, 2009. This decrease was partially offset by a
moderate increase in bad debt expense related to our revenue cycle management business.
Our sales, marketing, general and administrative expense for our pharmacy services segment was
approximately $5.4 million for the nine months ended September 30, 2009 as compared to $2.9 million
for the nine months ended September 30, 2008, an increase of approximately $2.5 million, or 87.8%.
Sales, marketing, general and administrative expense for our pharmacy services segment includes
approximately $0.4 million and $0.0 million related to equity-based compensation for the nine
months ended September 30, 2009 and September 30, 2008, respectively. Excluding this equity-based
compensation, pharmacy services sales, marketing, general and administrative expense was $5.1
million for the nine months ended September 30, 2009 as compared to $2.9 million for the nine
months ended September 30, 2008, an increase of approximately $2.2 million, or 75.9%. This increase
is primarily related to the inclusion of the infrastructure associated with our acquisition of eRx
on July 2, 2009, which is presently being integrated with our historical pharmacy services
infrastructure.
Corporate Expense
Our corporate expense was $36.1 million for the nine months ended September 30, 2009 as
compared to $25.3 million for the nine months ended September 30, 2008, an increase of
approximately $10.7 million, or 42.4%. Corporate expense includes approximately $7.3 million and
$2.4 million related to equity-based compensation for the nine months ended September 30, 2009 and
September 30,
44
2008, respectively. Excluding this equity-based compensation, corporate expense was
$28.8 million for the nine months ended September 30, 2009 as compared to $23.0 million for the
nine months ended September 30, 2008, an increase of approximately $5.8 million, or 25.4%. This
increase in the current year period was primarily due to (i) incremental costs associated with
building the infrastructure required to operate as a public company,
such as increased directors
and officers liability insurance costs, increased compliance costs and additional finance, legal and other personnel costs, (ii)
expenses associated with the IPO (including the costs of related amendments to our credit agreements) and (iii)
costs of added corporate functions, including business development and public relations, not
included in the prior year period.
Depreciation and Amortization Expense
Our depreciation and amortization expense was $77.1 million for the nine months ended
September 30, 2009 as compared to $72.0 million for the nine months ended September 30, 2008, an
increase of approximately $5.1 million, or 7.0%. This increase was primarily due to depreciation of
property and equipment placed in service subsequent to September 30, 2008, as well as additional
depreciation and amortization expense related to purchase accounting adjustments associated with
the 2008 Transaction, the GE Patient Statement Acquisition and the eRx acquisition which occurred in February
2008, September 2008 and July 2009, respectively. The increased depreciation and amortization from
the 2008 Transaction is fully reflected in the nine months ended September 30, 2009 while only
reflected for the period from February 8, 2008 to September 30, 2008 in the nine months ended
September 30, 2008.
Interest Income
We had minimal interest income for the nine months ended September 30, 2009 as compared to
$0.9 million for the nine months ended September 30, 2008, a decrease of approximately $0.9
million. While our interest-bearing cash and cash equivalent balances have increased since
September 30, 2008, this increase was more than offset by the effect of a reduction in the market
interest rates available to us during the nine months ended September 30, 2009.
Interest Expense
Our interest expense was $52.3 million for the nine months ended September 30, 2009 as
compared to $49.9 million for the nine months ended September 30, 2008, an increase of
approximately $2.4 million, or 4.9%. The comparability of interest expense between these two nine
month periods is impacted by the adjustment of 48% of our debt to its fair value in connection with
the 2008 Transaction, the discontinuation of hedge accounting treatment for our interest rate swap
from February 2008 to September 2008, a decrease in the notional amount of our interest rate swap
agreement, as well as a decline in the variable interest rates under our credit agreements. Both
the adjustment of 48% of our debt to fair value and the discontinuation of hedge accounting
treatment of our interest rate swap resulted in increased interest expense from the amortization of
such items. This increased amortization is fully reflected in the nine months ended September 30,
2009 while only reflected for the period from February 8, 2008 to September 30, 2008 in the nine
months ended September 30, 2008.
Our discontinuation of hedge accounting treatment in 2008 also required us to adjust our
interest rate swap to fair market value with the change reflected in interest expense. The nine
months ended September 30, 2008 included a reduction of interest expense of approximately $12.7
million related to this fair value adjustment. No similar adjustment was reflected in the nine
months ended September 30, 2009 as we redesignated our interest rate swap agreement as a hedge of
our interest rate risk in September 2008.
Income Taxes
Our income tax expense was $12.9 million for the nine months ended September 30, 2009 as
compared to $11.2 million for the nine months ended September 30, 2008, an increase of
approximately $1.7 million, or 15.0%. The effective income tax rates for the nine months ended
September 30, 2009 and September 30, 2008 were 58.1% and 59.1%, respectively. Differences between
the federal statutory rate and these effective income tax rates principally relate to the change in
our book basis versus tax basis in our investment in EBS Master, changes in our valuation
allowance, including the effect of income allocated to a noncontrolling interest, valuation
allowance changes, state income tax rate changes and the impact of other permanent differences
relating to pre-tax income.
45
Liquidity and Capital Resources
General
We are a holding company with no material business operations. Our principal asset is the
equity interests we own in EBS Master. We conduct all of our business operations through the direct
and indirect subsidiaries of EBS Master. Accordingly, our only material sources of cash are the IPO
proceeds and dividends or other distributions or payments that are derived from earnings and cash flow
generated by the subsidiaries of EBS Master.
We historically financed our operations primarily through cash provided by operating
activities, private sales of EBS Units to the Principal Equityholders and borrowings under our
credit agreements. On August 17, 2009, we closed the IPO and received net proceeds (excluding
offering related expenses of approximately $3.1 million paid during 2008) of approximately $148.3
million. We used approximately $5.4 million of our net proceeds from this offering to purchase EBS
Units held by certain senior executives and will use any remaining proceeds for working capital and
general corporate purposes, which may include the repayment of indebtedness and to fund future
acquisitions. We believe that our existing cash on hand, the net proceeds from our IPO, cash
generated from operating activities and available borrowings under our revolving credit agreement
($44.2 million as of September 30, 2009) will be sufficient to service our existing debt, finance
internal growth, fund capital expenditures and fund small to mid-size acquisitions.
As of September 30, 2009, we had cash and cash equivalents of $195.0 million as compared to
$71.5 million as of December 31, 2008.
With the exception of the use of approximately $74.6 million in cash to fund the eRx
acquisition, we have generally retained the cash generated from our operations since 2007 primarily
as a result of the general weakening of the global economy and its implications for the credit
markets. Our cash balances in the future may be reduced if we expend our cash on capital
expenditures, future acquisitions or elect to make optional prepayments under our credit
agreements. In addition, if as a result of the current conditions in the credit markets, any of the
lenders participating in our revolving credit agreement become insolvent, it may make it more
difficult for us to borrow under our revolving credit agreement, which could adversely affect our
liquidity. Credit market instability also may make it more difficult for us to obtain additional
financing or refinance our existing credit facilities in the future on acceptable terms. If we were
unable to obtain such additional financing when needed or were unable to refinance our credit
facilities, our financial condition could be adversely affected.
Cash Flows
Operating Activities
Cash provided by operations for the nine months ended September 30, 2009 was $121.1 million as
compared to $62.3 million for the nine months ended September 30, 2008. This $58.8 million increase
primarily reflects increased collections, net of payments associated with business growth, reduced
interest payments and timing of payments at the end of 2008 as compared to the end of September
2009.
Investing Activities
Cash used in investing activities for the nine months ended September 30, 2009 was $106.4
million as compared to $339.3 million for the nine months ended September 30, 2008. Excluding
payments related to the 2008 Transaction of $306.3 million and payments related to acquisitions
totaling approximately $92.5 million (net of cash acquired), cash used in investing activities was
$30.6 million for the nine months ended September 30, 2009 as compared to $16.3 million for the
nine months ended September 30, 2008. The remaining increase in cash used in investing activities
for the nine months ended September 30, 2009 is primarily due to capital expenditures, which have
increased as compared to the prior year period due to the timing and extent of efficiency measures
and product development projects.
46
Financing Activities
Cash provided by financing activities for the nine months ended September 30, 2009 was $108.9
million as compared to $301.4 million provided for the nine months ended September 30, 2008.
Excluding items related to the 2008 Transaction of $307.5 million in the nine months ended
September 30, 2008 and proceeds from the IPO of our Class A common stock of $148.3 million
(excluding approximately $3.1 million of offering related expenses paid in 2008) in the nine months
ended September 30, 2009, cash used in financing activities was $39.4 million for the nine months
ended September 30, 2009 as compared to $6.0 million used for the nine months ended September 30,
2008. The remaining decrease in cash provided by financing activities for the nine months ended
September 30, 2009 was attributable to (i) repurchases of $1.6 million of our Class A common stock
(to satisfy employee income tax withholding requirements) following the IPO, (ii) repurchases of
$5.4 million of EBS Units in connection with the IPO, (iii) a $10.0 million repayment of a revolver draw and
(iv) additional debt payments of $16.0 million on our first lien credit facility.
Credit Facilities
In November 2006, our subsidiary, EBS LLC, entered into the first lien credit agreement, which
we refer to as the First Lien Credit Agreement, and the second lien credit agreement, which we
refer to as the Second Lien Credit Agreement. Together, we refer to the First Lien Credit
Agreement and the Second Lien Credit Agreement as the Credit Agreements. The First Lien Credit
Agreement provided us $805.0 million of total available financing, consisting of a secured $755.0
million term loan facility and a secured $50.0 million revolving credit facility. The revolving
credit facility provides for the issuance of standby letters of credit, in an aggregate face amount
at any time not in excess of $12.0 million. The issuance of standby letters of credit reduces the
available capacity under our revolving credit facility. In addition, under the terms of the First
Lien Credit Agreement, we can borrow up to an additional $200.0 million in incremental term loans
and increase the available capacity under the revolving credit facility by $25.0 million, provided
that the aggregate amount of such increases may not exceed $200.0 million.
Effective July 7, 2009, the Credit Agreements were amended to modify the definition of a
change in control and to provide EBS LLC with the right to fund certain tax obligations, as well
as accounting, legal and other costs of the Company (subject to an annual limit of $5.0 million of
these other costs). In connection with the amendment, the Company paid fees of approximately $0.4
million to the lenders of which the unamortized portion is classified as a reduction of the
carrying value of the credit agreements. Additionally, the Company incurred approximately $0.5
million of fees paid to third parties in connection with this amendment that were expensed in the
quarter ended September 30, 2009.
Borrowings outstanding under the First Lien Credit Agreement amounted to $688.2 million as of
September 30, 2009, and currently bear interest, at our option, at either an adjusted LIBOR rate
plus 2.00% or the lenders alternate base rate plus 1.00%, or a combination of the two. We are generally required to make quarterly principal payments of
approximately $1.8 million on the term loan facilities of the First Lien Credit Agreement through
2013.
We are required to pay a commitment fee of 0.5% per annum, if our total leverage ratio is
greater than or equal to 4.0:1, and otherwise 0.375% per annum on the undrawn portion of the
revolving credit facility. We are permitted to prepay the revolving credit facility or the term
loan under the First Lien Credit Agreement at any time. We are required to prepay amounts
outstanding under the First Lien Credit Agreement with proceeds we receive from asset sales that
generate proceeds in excess of $1.0 million, from indebtedness we incur that is not permitted under
the First Lien Credit Agreement and with any excess cash flow (as defined in the First Lien Credit
Agreement) we generate in any fiscal year.
Our Second Lien Credit Agreement is a term loan facility with an aggregate principal amount of
$170.0 million, which was the amount outstanding as of September 30, 2009. Borrowings outstanding
under the Second Lien Credit Agreement currently bear interest, at our option, at either an
adjusted LIBOR rate plus 5.00% or the lenders alternate base rate plus 4.00%, or a combination of
the two. We are required to make quarterly interest payments. Although we are permitted to prepay
the loans under our Second Lien Credit Agreement at any time, the terms of our First Lien Credit
Agreement restrict our ability to make such prepayments to the amount of previous years retained
excess cash flow (as defined under the First Lien Credit Agreement) and only if our total leverage
ratio is 4.0 to 1 or better.
The revolving portion of the First Lien Credit Agreement matures in November 2012 and the term
loan matures in November 2013. The Second Lien Credit Agreement matures in May 2014. We anticipate
refinancing our Credit Agreements prior to or as of their maturity dates. Given the state of the
current credit environment resulting from, among other things, a general weakening of the
economy, we cannot be certain that we will be successful in our refinancing efforts on
acceptable terms, which could have an adverse effect on our liquidity.
47
The obligations of EBS LLC under the Credit Agreements are unconditionally guaranteed by EBS
Master and all of its subsidiaries and are secured by liens on substantially all of EBS Masters
assets, including the stock of its subsidiaries.
As of September 30, 2009, total borrowings outstanding under the Credit Agreements amounted to
$858.2 million (before unamortized debt discount of $56.3 million
primarily related to the adjustment of our long-term debt to fair value in connection with the 2008 Transaction). Under the revolving portion of our First
Lien Credit Agreement, net of $5.8 million of outstanding but undrawn letters of credit issued, we
had $44.2 million in available borrowing capacity.
During the nine months ended September 30, 2009, the weighted average cash interest rate of
our borrowings under our Credit Agreements was approximately 5.7%.
Covenants
The Credit Agreements require us to satisfy specified financial covenants, including a minimum
interest coverage ratio and a maximum total leverage ratio, as set forth in the Credit Agreements.
The minimum interest coverage ratio permitted was 2.25:1.00 at September 30, 2009 and increases at
varying intervals over time until October 1, 2011, at which time it is fixed at 3.50:1.00. At
September 30, 2009, our interest coverage ratio as defined under the Credit Agreements was 4.31 to
1.00. The maximum total leverage ratio permitted was 5.00:1.00 at September 30, 2009 and declines
at varying intervals over time until October 1, 2011, at which time it is fixed at 3.00:1.00. At
September 30, 2009, our total leverage ratio was 3.52 to 1.00 which, under the terms of the Credit
Agreement, reflected only $35.0 million of the cash on our balance sheet at September 30, 2009 as a
reduction of our net debt.
The Credit Agreements also limit us with respect to amounts we may spend on capital
expenditures. The limitation varies based on certain base expenditure levels included in the Credit
Agreements and the amount of unused capital expenditures from the previous calendar year, if any,
as well as allowable amounts transferred from future year expenditure limits. Under the Credit
Agreements, for the year ended December 31, 2009, our capital expenditures are limited to $67.0
million which includes a carryover of unused capital expenditures from 2008, as well as allowable
transfers from 2010. For the years ended December 31, 2010 and 2011, our capital expenditures are
limited annually to $40.0 million and $41.0 million, respectively, excluding any carryovers from
previous years and allowable transfers from future years. For years ending after December 31, 2011,
our capital expenditures are limited to $42.0 million annually, excluding any carryovers from
previous years and allowable transfers from future years. In addition to our normal level of
capital expenditures, we currently expect to incur up to $25.0 million in 2010 and 2011 to replace
our primary data center in Nashville, Tennessee. We currently intend to fund investments in our new
data center from operating cash flows or our revolving credit facility.
The Credit Agreements contain negative covenants that may restrict the operation of our
business, including our ability to incur additional debt, create liens, make investments, engage in
asset sales, enter into transactions with affiliates, enter into sale-leaseback transactions and
enter into hedging arrangements. In addition, our Credit Agreements restrict the ability of EBS
Master and its subsidiaries to make dividends or other distributions to us, issue equity interests,
repurchase equity interests or certain indebtedness or enter into mergers or consolidations.
As of September 30, 2009, we were in compliance with all of the financial and other covenants
under the Credit Agreements.
The Credit Agreements do not contain provisions that would accelerate the maturity date of the
loans under the Credit Agreement upon a downgrade in our credit rating. However, a downgrade in our
credit rating could adversely affect our ability to obtain other capital sources in the future and
could increase our cost of borrowings.
Events of default under the Credit Agreements include non-payment of principal, interest, fees
or other amounts when due; violation of certain covenants; failure of any representation or
warranty to be true in all material respects when made or deemed made; cross-default and
cross-acceleration to indebtedness with an aggregate principal amount in excess of $20.0 million;
certain ERISA events; dissolution, insolvency and bankruptcy events; actual or asserted invalidity
of the guarantees or security documents; and a Change of Control (as such term is defined in the
Credit Agreements). Some of these events of default allow for grace periods and materiality
qualifiers.
48
Commitments and Contingencies
The Registration Statement discloses certain commitments and contractual obligations that
existed as of December 31, 2008. The following paragraphs describe the significant additional
commitments and contractual obligations that have arisen subsequent to the effective date of the
Registration Statement.
Upon the closing of our IPO, we entered into tax receivable agreements which obligate us to
make payments to certain parties affiliated with General Atlantic and H&F and former Grant Unit
holders generally equal to 85% of the applicable cash savings that we realize as a result
of tax attributes arising from the 2006 Transaction, the 2008 Transaction and exchanges of EBS
Units for cash or shares of our Class A common stock. We will retain the benefit of the remaining
15% of these tax savings. We estimate that these payments will total
approximately $141.7 million
over the life of the tax receivable agreements with payments expected to begin during 2011.
In connection with our acquisition of eRx, we assumed an operating lease agreement for
approximately 19,000 square feet of office space in Fort Worth Texas. The initial term of the
lease is approximately 10 years (cancellable after approximately 5 years) with a base initial
annual rental of approximately $0.4 million.
In August 2009, we executed a lease for approximately 34,000 square feet of space in a
building that is to be constructed to house our primary data center in Nashville, Tennessee. The
initial term of the lease is 15 years with a base initial annual
rental of approximately $0.5 million.
Off-Balance Sheet Arrangements
As of September 30, 2009, we had no off-balance sheet arrangements or obligations, other than
those related to our letters of credit, our interest rate swap agreement, and surety bonds of an
insignificant amount.
Recent Accounting Pronouncements
On January 1, 2009, the Company adopted the FASB ASC Business Combinations Topic. This topic
expands the definition of a business and a business combination and generally requires the
acquiring entity to recognize all of the assets and liabilities of the acquired business,
regardless of the percentage ownership acquired, at their fair
values. This topic also requires that
contingent consideration and certain acquired contingencies be recorded at fair value on the
acquisition date and that acquisition costs generally be expensed as incurred. The Company recorded
approximately $0.4 million of acquisition related expenses in the nine months ended September 30,
2009 that, absent the adoption of this topic would have been
capitalized. These costs are included in the accompanying unaudited
condensed consolidated statement of operations within sales,
marketing, general and administrative expenses. Net income for the nine
months ended September 30, 2009 was reduced by approximately $0.2 million ($0.00 per diluted Class
A share).
On January 1, 2009, the Company adopted the provisions of the FASB ASC Fair Value Measurements
and Disclosures Topic that related to nonfinancial assets and liabilities that are not required or
permitted to be measured at fair value on a recurring basis. Examples of such circumstances include
fair value measurements associated with the initial recognition of assets and liabilities in a
business combination and measurements of impairment following a goodwill impairment test or an
impairment of a long-lived asset other than goodwill. The adoption of this topic had no material
impact on the Companys unaudited condensed consolidated financial statements for the nine months
ended September 30, 2009.
On January 1, 2009, the Company adopted the FASB ASC Consolidation Topic as it relates to
noncontrolling interests in consolidated financial statements. The topic clarifies that a
noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that
should be reported as equity in the consolidated financial statements. Additionally, the topic
changes the way the consolidated income statement is presented by requiring consolidated net income
to be reported at amounts that include the amounts attributable to both the parent and the
noncontrolling interest. The presentation and disclosure requirements of the topic have been given
retroactive effect for all periods presented.
On January 1, 2009, the Company adopted additional disclosure provisions of the FASB ASC
Derivatives and Hedging Topic. The additional provisions amended and expanded the disclosure
requirements for derivative instruments and hedging activities with the intent to provide users of
financial statements with an enhanced understanding of how and why an entity uses derivative
instruments; how derivative instruments and related hedged items are accounted for; and how
derivative instruments and related hedged items
49
affect an entitys financial position, financial
performance, and cash flows. The topic requires qualitative disclosures about objectives and
strategies for using derivatives, quantitative disclosures about fair value amounts of gains and
losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements. The
required disclosures are presented within Note 7 to the
Companys unaudited condensed consolidated financial
statements.
On April 1, 2009, the Company adopted provisions of the FASB ASC Fair Value Measurements and
Disclosures Topic (formerly outlined in FASB Staff Position 157-4, Determining Fair Value When the
Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and
Identifying Transactions That Are Not Orderly). Provisions of this topic provide additional
guidance for estimating fair value in accordance with the topic when the volume and level of
activity for the asset or liability have significantly decreased and re-emphasizes that a fair
value measurement is an exit price concept as defined in the topic. Assets and liabilities measured
under Level 1 inputs are excluded from the scope of these provisions. The adoption of these
provisions had no material impact on the Companys unaudited condensed consolidated financial
statements for the nine months ended September 30, 2009.
On April 1, 2009, the Company adopted provisions of the FASB ASC Fair Value Measurements and
Disclosures Topic (formerly outlined in FASB Staff Position No. 107-1 and Accounting Principles
Board Opinion 28-1, Interim Disclosures about Fair Value of Financial Instruments), to provide
disclosures on the fair value of financial instruments in interim financial statements. The
disclosures required by the topic are presented within Note 8 to the
Companys unaudited condensed
consolidated financial statements.
On April 1, 2009, the Company adopted the FASB ASC Subsequent Events Topic. The topic
establishes general standards of accounting for and disclosure of events that occur after a
companys balance sheet date but before financial statements of the company are issued or are
available to be issued. In particular, this topic sets forth: (i) the period after the balance
sheet date during which management of a reporting entity should evaluate events or transactions
that may occur for potential recognition or disclosure in the financial statements, (ii) the
circumstances under which an entity should recognize events or transactions occurring after the
balance sheet date in its financial statements and (iii) the disclosures that an entity should make
about events or transactions that occurred after the balance sheet date. Additionally, the topic
requires companies to disclose the date through which subsequent events have been evaluated as well
as the date the financial statements were issued or were available to be issued. The adoption of
the topic had no material impact on the Companys consolidated financial statements for the nine
months ended September 30, 2009. The disclosures required by the topic are presented within Note 18
to the Companys unaudited condensed consolidated financial statements.
In August 2009, the FASB issued Accounting Standards Update 2009-05, an update to FASB ASC
Fair Value Measurements and Disclosures Topic. This update clarifies the valuation techniques to be
used by an entity to measure the fair value of a liability in circumstances in which a quoted price
in an active market for the identical liability is not available. The update further clarifies that
when estimating the fair value of a liability, a reporting entity is not required to include a
separate input or adjustment to other inputs relating to the existence of a restriction that
prevents the transfer of the liability. The guidance provided in this update is effective beginning
October 1, 2009 and is not expected to have a material impact on the consolidated financial
statements of the Company.
|
|
|
ITEM 3. |
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
We have interest rate risk primarily related to borrowings under the Credit Agreements. Term
loan borrowings under the First Lien Credit Agreement bear interest, at our option, at either an
adjusted LIBOR rate plus 2.00% or the lenders alternate base rate plus 1.00%, or a combination of
the two, and borrowings under the Second Lien Credit Agreement bear interest, at our option, at
either an adjusted LIBOR rate plus 5.00% or the lenders alternate base rate plus 4.00%, or a
combination of the two. As of September 30, 2009, we had outstanding borrowings (before unamortized
debt discount of $56.3 million) of $688.2 million under the First Lien Credit Agreement and $170.0
million under the Second Lien Credit Agreement.
We manage our interest rate risk through the use of an interest rate swap agreement. Effective
December 31, 2006, we entered into an interest rate swap to exchange three month LIBOR rates for
fixed interest rates, resulting in the payment of an all-in fixed rate of 4.944% on an initial
notional amount of $786.3 million which amortizes on a quarterly basis until maturity at December
30, 2011. At September 30, 2009, the notional amount of the interest rate swap was $478.8 million.
As a result, as of September 30, 2009, $379.4 million of our total borrowings were effectively
subject to a variable interest rate. Our notional amount is further scheduled to decrease by an
additional $123.6 million on December 31, 2009.
50
A change in interest rates on variable rate debt impacts our pre-tax earnings and cash flows.
Since its redesignation on September 30, 2008, our interest rate swap qualifies for hedge
accounting as a cash flow hedge. Therefore, future changes in market fluctuations related to the
effective portion of this cash flow hedge do not impact our pre-tax earnings until the accrued
interest is recognized on the derivative and the associated hedged debt. Based on our outstanding
debt as of September 30, 2009 and assuming that our mix of debt instruments, interest rate swap and other variables remain the same, the annualized
effect of a one percentage point change in variable interest rates
would have a
pre-tax impact on
our earnings and cash flows of approximately $4.7 million.
The interest rate swap is accounted for in accordance with FASB ASC Derivatives and Hedging
Topic which establishes accounting and reporting standards for derivative instruments and hedging
activities and requires that all derivatives be recognized as either assets or liabilities at fair
value.
In the future, in order to manage our interest rate risk, we may enter into additional
interest rate swaps, modify our existing interest rate swap or make changes that may impact our
ability to treat our interest rate swap as a cash flow hedge.
|
|
|
ITEM 4. |
|
CONTROLS AND PROCEDURES |
Disclosure Controls and Procedures
Under the supervision and with the participation of our Chief Executive Officer and Chief
Financial Officer, management has evaluated the effectiveness of the design and operation of our
disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities
Exchange Act of 1934) as of September 30, 2009. Based upon that evaluation, our Chief Executive
Officer and Chief Financial Officer concluded that, as of September 30, 2009, our disclosure
controls and procedures were effective in causing material information relating to us (including
our consolidated subsidiaries) to be recorded, processed, summarized and reported by management on
a timely basis and to ensure the quality and timeliness of our public disclosures with SEC
disclosure obligations.
Our management, including our Chief Executive Officer and Chief Financial Officer, does not
expect that our disclosure controls and procedures will prevent all errors and all fraud. A control
system, no matter how well conceived and operated, can provide only reasonable, not absolute,
assurance that the objectives of the control system are met. Further, the design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must
be considered relative to their costs. Because of the inherent limitations in all control systems,
no evaluation of controls can provide absolute assurance that all control issues and instances of
fraud, if any, with the Company have been detected. These inherent limitations include the
realities that judgments in decision-making can be faulty and that breakdowns can occur because of
simple error and mistake. Additionally, controls can be circumvented by the individual acts of some
persons, by collusion of two or more people or by management override of controls.
The design of any system of controls also is based in part upon certain assumptions about the
likelihood of future events, and there can be no assurance that any design will succeed in
achieving its stated goals under all potential future conditions; over time, a control may become
inadequate because of changes in conditions or the degree of compliance with the policies or
procedures may deteriorate. Because of the inherent limitations in a cost-effective control system,
misstatements due to error or fraud may occur and may not be detected.
Changes in Internal Control Over Financial Reporting
There has been no change to our internal control over financial reporting during the quarter
ended September 30, 2009 that has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.
51
PART II. OTHER INFORMATION
|
|
|
ITEM 1. |
|
LEGAL PROCEEDINGS |
In the normal course of business, the Company is subject to claims, lawsuits and legal
proceedings. While it is not possible to ascertain the ultimate outcome of such matters, in
managements opinion, the liabilities, if any, in excess of amounts provided or covered by
insurance, are not expected to have a material adverse effect on our consolidated financial
position, results of operations or liquidity.
The discussion of the Companys business and operations should be read together with the risk
factors contained in Risk Factors of our Registration Statement, which describes various risks
and uncertainties to which we are or may be subject. These risks and uncertainties have the
potential to affect our business, financial condition, results of operations, cash flows and
prospects in a material adverse manner. As of September 30, 2009, there have been no material
changes to the risk factors set forth in our Registration Statement.
|
|
|
ITEM 2. |
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
Initial Public Offering
On August 11, 2009, the Company commenced the IPO of its Class A common stock, par value of
$0.0001. Pursuant to the Registration Statement on Form S-1 (File No. 333-153451), as amended, that
was declared effective on August 11, 2009 and its Registration Statement on Form S-1MEF (File No.
333-161270) (collectively, the Registration Statements), the Company registered 27,255,000 shares
of Class A common stock, consisting of 10,725,000 Class A shares on behalf of the Company and
16,530,000 Class A shares on behalf of the selling stockholders (including 3,555,000 Class A shares
representing an over-allotment option granted by the selling stockholders to the underwriters in
the IPO). The Class A common stock was registered at a proposed maximum offering price of $422.5
million pursuant to the Registration Statements. The entirety of the Class A common stock was sold
in the IPO at a price per share to the public of $15.50 for an aggregate offering price of $422.5
million. Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co., UBS Securities LLC, Barclays
Capital Inc. acted as joint book-running managers of the offering and as representatives of the
underwriters. The IPO closed on August 17, 2009, and the net proceeds of the IPO to the Company
were $145.2 million (including approximately $3.1 million of offering expenses paid in 2008),
determined as follows (in thousands):
|
|
|
|
|
Aggregate offering proceeds to the Company |
|
$ |
166,238 |
|
Underwriting discounts and commissions |
|
|
(10,805 |
) |
Other fees and expenses |
|
|
(10,222 |
) |
|
|
|
|
Total fees |
|
$ |
(21,027 |
) |
|
|
|
|
Net proceeds to the Company |
|
$ |
145,211 |
|
|
|
|
|
As of September 30, 2009, we have used approximately $5.4 million of the proceeds from our IPO
to purchase 370,760 EBS Units held by certain EBS Equity Plan participants. We anticipate that we
will use the remaining net proceeds from the IPO for working capital and other general corporate
purposes. Prior to application of such proceeds, we may hold the net proceeds in cash or invest
them in short-term securities or investments. There has been no material change in the planned use
of the IPO net proceeds from that described in the Registration Statements.
Issuances of Class A and Class B common stock
On August
4, 2009, the Company issued 22,586,390 shares of Class B common stock
at a purchase price of $0.00001 per share to affiliates of H&F
in connection with the reorganization transactions. The shares of
Class B common stock were issued in a private offering pursuant to
Section 4(2) of the Securities Act, as amended, and the rules and
regulations promulgated thereunder. On August 12, 2009, the Company issued an aggregate of 2,537,325 shares of Class B common
stock at a purchase price of $0.00001 per share to certain members of the Companys senior
management and Board of Directors. The shares of Class B common stock were issued in a private
offering pursuant to Section 4(2) of the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder. Additionally, on August 12, 2009, the Company issued an
aggregate of 1,850,000 shares of Class A common stock to the members of eRx that received EBS Units
as partial consideration for the Companys acquisition of eRx in exchange for all 1,850,000 EBS
Units (and corresponding shares of Class B common stock) previously held by them. The shares of
52
Class A common stock were issued in a private offering pursuant to Section 4(2) of the
Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
|
|
|
ITEM 3. |
|
DEFAULTS UPON SENIOR SECURITIES |
Not Applicable.
|
|
|
ITEM 4. |
|
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS |
Pursuant to a Written Consent of the Stockholders to Take Action Without a Meeting dated as of
July 20, 2009, the stockholders of the Company approved the following proposals:
(i) Approval of a Certificate of Amendment to the Certificate of Incorporation of the Company
in order to increase the number of authorized shares of common stock of the Company from 600,000
shares to 65,000,000 shares and to change the par value of each share of common stock of the
Company from $0.01 per share to $0.00001 per share.
|
|
|
|
|
Votes Cast For |
|
Votes Against/Withheld |
|
Votes Abstaining |
520,000
|
|
0
|
|
0 |
(ii) Approval of a proposal to effect a stock split with respect to the common stock of the
Company, such that each share of Company common stock then issued and outstanding would be
converted into 107.692308 shares of common stock of the Company following the stock split.
|
|
|
|
|
Votes Cast For |
|
Votes Against/Withheld |
|
Votes Abstaining |
520,000
|
|
0
|
|
0 |
(iii) Approval of the Amended and Restated Certificate of Incorporation of the Company,
subject to and effective upon the closing of the IPO.
|
|
|
|
|
Votes Cast For |
|
Votes Against/Withheld |
|
Votes Abstaining |
520,000
|
|
0
|
|
0 |
(iv) Approval of the 2009 Plan.
|
|
|
|
|
Votes Cast For |
|
Votes Against/Withheld |
|
Votes Abstaining |
520,000
|
|
0
|
|
0 |
(v) Approval of the Emdeon Inc. Employee Stock Purchase Plan.
|
|
|
|
|
Votes Cast For |
|
Votes Against/Withheld |
|
Votes Abstaining |
520,000
|
|
0
|
|
0 |
Not Applicable.
The exhibits listed on the accompanying Exhibit Index are filed, furnished or incorporated by
reference (as stated therein) as part of this Quarterly Report.
53
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
Date: November 12, 2009 |
By: |
/s/ George I. Lazenby
|
|
|
|
George I. Lazenby, Chief Executive Officer and Director |
|
|
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
|
|
|
Date: November 12, 2009 |
By: |
/s/ Bob A. Newport
|
|
|
|
Bob A. Newport, Jr., Chief Financial Officer |
|
|
|
(Principal Financial and Accounting Officer) |
|
|
54
Exhibit Index
|
|
|
Exhibit No. |
|
|
|
|
|
2.3
|
|
Agreement and Plan of Merger, dated as of July 2, 2009, by and
among EBS Master LLC, Envoy LLC, Emdeon Merger Sub LLC, eRx
Network, L.L.C., and Longhorn Members Representative, LLC
(included as Exhibit 2.3 to the Companys Registration
Statement on Form S-1, as amended (File No. 333-153451), filed
on July 28, 2009, and incorporated herein by reference). |
|
|
|
3.1
|
|
Amended and Restated Certificate of Incorporation of Emdeon
Inc. (included as Exhibit 3.1 to the Companys Current Report
on Form 8-K, filed on August 17, 2009, and incorporated herein
by reference). |
|
|
|
3.2
|
|
Amended and Restated By-laws of Emdeon Inc. (included as
Exhibit 3.2 to the Companys Current Report on Form 8-K, filed
on August 17, 2009, and incorporated herein by reference). |
|
|
|
4.1
|
|
Specimen Class A common stock Certificate (included as Exhibit
4.1 to the Companys Registration Statement on Form S-1, as
amended (File No. 333-153451), filed on July 28, 2009, and
incorporated herein by reference). |
|
|
|
4.4
|
|
Amendment No. 2 to First Lien Credit Agreement, dated as of
July 7, 2009, among GA EBS Merger, LLC, as borrower,
Medifax-EDI Holding Company, as additional borrower, EBS
Master LLC, the lenders party thereto, Citibank, N.A., as
administrative agent, collateral agent, Swingline Lender and
Issuing Bank (included as Exhibit 4.4 to the Companys
Registration Statement on Form S-1, as amended (File No.
333-153451), filed on July 9, 2009, and incorporated herein by
reference). |
|
|
|
4.6
|
|
Amendment No. 1 to the Second Lien Credit Agreement, dated as
of July 7, 2009, among GA EBS Merger, LLC, as borrower,
Medifax-EDI Holding Company, as additional borrower, EBS
Master LLC, the lenders party thereto, Citibank, N.A., as
administrative agent, collateral agent, Swingline Lender and
Issuing Bank (included as Exhibit 4.6 to the Companys
Registration Statement on Form S-1, as amended (File No.
333-153451), filed on July 9, 2009, and incorporated herein by
reference). |
|
|
|
10.1
|
|
Reorganization Agreement, dated as of August 4, 2009, by and
among EBS Master LLC, Emdeon Inc. and the other parties named
therein (included as Exhibit 10.1 to the Companys Current
Report on Form 8-K, filed on August 17, 2009, and incorporated
herein by reference). |
|
|
|
10.2
|
|
Stockholders Agreement, dated as of August 5, 2009, by and
among Emdeon Inc. and the stockholders named therein (included
as Exhibit 10.2 to the Companys Current Report on Form 8-K,
filed on August 17, 2009, and incorporated herein by
reference). |
|
|
|
10.3
|
|
Sixth Amended and Restated Limited Liability Company Agreement
of EBS Master LLC, dated August 17, 2009 (included as Exhibit
10.3 to the Companys Current Report on Form 8-K, filed on
August 17, 2009, and incorporated herein by reference). |
|
|
|
10.4
|
|
Investor Tax Receivable Agreement by and among Emdeon Inc. and
the other parties named therein (Exchanges), dated August 17,
2009 (included as Exhibit 10.4 to the Companys Current Report
on Form 8-K, filed on August 17, 2009, and incorporated herein
by reference). |
|
|
|
10.5
|
|
Investor Tax Receivable Agreement by and among Emdeon Inc. and
the other parties named therein (Reorganizations), dated
August 17, 2009 (included as Exhibit 10.5 to the Companys
Current Report on Form 8-K, filed on August 17, 2009, and
incorporated herein by reference). |
|
|
|
10.6
|
|
Management Tax Receivable Agreement by and among Emdeon Inc.
and the persons named therein, dated August 17, 2009 (included
as Exhibit 10.6 to the Companys Current Report on Form 8-K,
filed on August 17, 2009, and incorporated herein by
reference). |
55
|
|
|
Exhibit No. |
|
|
|
|
|
10.7
|
|
Agreement and Plan of Merger, dated as of August 5, 2009, by
and among H&F Harrington, Inc., EBS Holdco II, LLC and Emdeon
Inc. (included as Exhibit 10.7 to the Companys Current Report
on Form 8-K, filed on August 17, 2009, and incorporated herein
by reference). |
|
|
|
10.8
|
|
Agreement and Plan of Merger, dated as of August 5, 2009, by
and among EBS Acquisition II, LLC, EBS Holdco I, LLC and
Emdeon Inc. (included as Exhibit 10.8 to the Companys Current
Report on Form 8-K, filed on August 17, 2009, and incorporated
herein by reference). |
|
|
|
10.9
|
|
Unit Purchase Agreement, dated August 11, 2009, by and among
Emdeon Inc. and the Sellers named therein (included as Exhibit
10.9 to the Companys Current Report on Form
8-K, filed on August 17, 2009, and incorporated herein by
reference). |
|
|
|
10.10
|
|
Lease Agreement, dated August 24, 2009, between Solomon
Airpark, LLC and Emdeon Business Services LLC (included as
Exhibit 10.1 to the Companys Current Report on Form 8-K,
filed on August 25, 2009, and incorporated herein by
reference). |
|
|
|
10.11
|
|
Form of Indemnification Agreement (included as Exhibit 10.1 to
the Companys Registration Statement on Form S-1, as amended
(File No. 333-153451), filed on July 9, 2009, and incorporated
herein by reference). |
|
|
|
10.13
|
|
Employment Agreement, dated July 21, 2009, among Bob A.
Newport and Emdeon Business Services LLC (included as
Exhibit 10.13 to the Companys Registration Statement on Form
S-1, as amended (File No. 333-153451), filed on July 28, 2009,
and incorporated herein by reference). |
|
|
|
10.14
|
|
Employment Agreement, dated July 7, 2009, among J. Philip
Hardin and Emdeon Business Services LLC (included as Exhibit
10.14 to the Companys Registration Statement on Form S-1, as
amended (File No. 333-153451), filed on July 9, 2009, and
incorporated herein by reference). |
|
|
|
10.15
|
|
Employment Agreement, dated July 7, 2009, among Gary Stuart
and Emdeon Business Services LLC (included as Exhibit 10.15 to
the Companys Registration Statement on Form S-1, as amended
(File No. 333-153451), filed on July 9, 2009, and incorporated
herein by reference). |
|
|
|
10.17
|
|
Emdeon Inc. 2009 Equity Incentive Plan (included as Exhibit
10.17 to the Companys Registration Statement on Form S-1, as
amended (File No. 333-153451), filed on July 28, 2009, and
incorporated herein by reference). |
|
|
|
10.24
|
|
Form of Common Stock Subscription and EBS Unit Vesting
Agreement (included as Exhibit 10.24 to the Companys
Registration Statement on Form S-1, as amended (File No.
333-153451), filed on July 28, 2009, and incorporated herein
by reference). |
|
|
|
10.25
|
|
Form of Emdeon Inc. Non-Qualified Stock Option Agreement
(included as Exhibit 10.25 to the Companys Registration
Statement on Form S-1, as amended (File No. 333-153451), filed
on July 28, 2009, and incorporated herein by reference). |
|
|
|
10.26
|
|
Emdeon Inc. Employee Stock Purchase Plan (included as Exhibit
10.26 to the Companys Registration Statement on Form S-1, as
amended (File No. 333-153451), filed on July 28, 2009, and
incorporated herein by reference). |
|
|
|
31.1
|
|
Certification of Chief Executive Officer required by Rule
13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934,
as amended, as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 (filed herewith). |
|
|
|
31.2
|
|
Certification of Chief Financial Officer required by Rule
13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934,
as amended, as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 (filed herewith). |
|
|
|
32.1
|
|
Certification of Chief Executive Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 (furnished herewith). |
|
|
|
32.2
|
|
Certification of Chief Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 (furnished herewith). |
56